Method for detection of antibodies

Abstract

A method of detecting an antibody of interest in a humoral fluid comprising: (a) spotting humoral fluid from a subject directly on a solid support thereby immobilizing antibodies within the humoral fluid directly onto the solid support ("spotted solid support"); (b) contacting the spotted solid support with a fusion protein comprising an antigen of the antibody of interest and a primary tag such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen; (c) contacting the spotted solid support contacted with the fusion protein with a secondary detection reagent conjugated to a detectable label, the secondary detection reagent having affinity for the primary tag of the fusion protein to form a complex; and (d) detecting presence of a signal from the detectable label. Also, a fusion protein comprising SpyCatcher2 conjugated to Apex2.

Description

[0001] TITLE

[0002] Method for Detection of antibodies

[0003] FIELD OF TECHNOLOGY

[0004] The present disclosure relates to a method for detecting antibodies.

[0005] BACKGROUND INFORMATION

[0006] Caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2), the Covid-19 pandemic has left an unimaginable impact on human life and the global economy (1 , 2). In response, research communities around the world have launched an intense campaign to develop diagnostic, therapeutic, and vaccination platforms. Among these, diagnostic platforms are particularly important for controlling the spread of the disease (3). Serological assays that can detect immunity following infection or vaccination have proven to be a key tool in the fight against Covid-19 (4). These assays can act as a complement for nucleic acid amplification tests (5, 6), are an integral part of vaccine development processes (7, 8), and can also be used to screen patient plasma specimens for convalescent plasma therapy (9). In addition, by providing insights into population immunity prevalence, serology assays inform governments on best pandemic response policies (10).

[0007] The scientific community has focused heavily on the development and characterisation of Covid-19 serological assays. These include Enzyme-Linked Immunosorbent Assays (ELISAs) (11-13), Chemiluminescence Immunoassays (CLIAs) (14), Virus Neutralization Assays (15, 16), Lateral Flow Assays (LFAs) (6, 17), and luminescent biosensor assays (18-20). All of these methods require costly or sophisticated reagents that are not easy to acquire or produce, especially during outbreaks. Furthermore, from a rapid response perspective the aforementioned methods can prove challenging to adapt and scale in-time, and in settings where they may be most needed (21 ). This is primarily due to the fact that the molecular (e.g. purified antigens, commercial antibody sets etc.) and material constituents (e.g. functionalised multi-well substrates, plate readers etc.) for such methods cannot always be readily accessed and assembled, despite the established methodological know-how.

[0008] A promising technology capable of addressing this diagnostics supply and accessibility bottleneck is cell-free synthetic biology (22, 23). This technology relies on extracted cellular gene expression machinery and thus can solve many limitations associated with conventional biologies manufacturing and distribution practices (24). Over the past decade, and prompted by the string of pathogenic outbreaks such as SARS CoV- 1 , Ebola Virus (EboV), Zika Virus, and the ongoing SARS CoV-2, there have been some ground-breaking demonstrations of novel cell-free synthetic biology-based diagnostics platforms (24-26).

[0009] To the best of our knowledge, all cell-free transcription-translation-based diagnostics methods published so far rely on nucleic acid (as opposed to antigen) -based detection of infection, and cell-free expression has mainly been used as a vehicle to operate gene circuit-based sensors. Whereas a major capacity of cell-free systems is the accelerated, on-demand production of functional biologies such as antigens (including bacterial antigens, viral antigens, fungal antigens, plant (for example pollen) antigens, animal antigens, chemical antigens, and so forth) and therapeutic antibodies (27, 28).

[0010] SUMMARY OF DISCLOSURE

[0011] In one embodiment, the present disclosure relates to a method of detecting an antibody of interest in a humoral fluid comprising: (a) spotting humoral fluid from a subject directly on a solid support thereby immobilizing antibodies within the humoral fluid directly onto the solid support (“spotted solid support”); (b) contacting the spotted solid support with a fusion protein comprising an antigen of the antibody of interest and a primary tag such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen; (c) contacting the spotted solid support contacted with the fusion protein with a secondary detection reagent conjugated to a detectable label, the secondary detection reagent having affinity for the primary tag of the fusion protein to form a complex; and (d) detecting presence of a signal from the detectable label, wherein presence of the signal from the detectable label indicates the presence of the antibody of interest in the humoral fluid.

[0012] In one embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the fusion protein is encoded from a linear DNA template in a cell-free expression reaction mixture or is provided in purified form.

[0013] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the primary tag and the secondary detection reagent comprise a SpyTag (or a SpyTag-sequence-specific nickel-assisted cleavage tag (SpyTag-SNAC tag)) and SpyCatcher; or Isopeptag and pilin-C; or SnoopTag and SnoopCatcher; or DogTag and SnoopTagJr; or SdyTag and SdyCatcher.

[0014] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the primary tag and the secondary detection reagent comprise a SpyTag and SpyCatcher. In one aspect, the SpyCatcher is produced by E. co / / -based expression system.

[0015] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the secondary detection reagent comprises SpyCatcher conjugated to a peroxidase, and wherein step (d) comprises (i) contacting the blotting membrane to a solution comprising hydrogen peroxide (H2O2) and at least one readout substrate, wherein the at least one readout substrate can be converted to a readout product in the presence of the H2O2, and (ii) detecting the presence of the readout product. In one aspect the peroxidase is Apex2 or HRP.

[0016] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the secondary reagent comprises SpyCatcher conjugated to a reporter that does not require exogenous hydrogen peroxide (for example a fluorescent or colorimetric reporter). In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the solid support is a nitrocellulose membrane, or a PVDF membrane or functionalized glass or plastic slides or beads.

[0017] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the solid support includes a grid of multiple spots, and wherein the humoral fluid is dispensed onto individual spots of the multiple spots.

[0018] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the humoral fluid is at least one of saliva, tears, mucus, breast milk, intestinal fluid, serum, plasma, blood, and vitreous fluid.

[0019] In another embodiment, the present disclosure provides for a kit for detecting an antibody of interest in a humoral fluid comprising: (a) a solid support for immobilizing antibodies in the humoral fluid; (b) a fusion protein comprising an antigen of the antibody of interest and a primary tag; (c) a secondary detection reagent conjugated to a detectable label; and (d) instructions for detecting the antibody of interest, wherein the instructions comprise: (i) spotting the humoral fluid from a subject directly on the solid support thereby immobilizing antibodies within the humoral fluid directly onto the blotting membrane (“spotted solid support”); (ii) contacting the spotted solid support with the fusion protein such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen; (iii) contacting the solid support contacted with the fusion protein with the secondary detection reagent conjugated to the detectable label; and (iv) detecting presence of a signal from the detectable label, wherein presence of the signal from the detectable label indicates the presence of the antibody of interest in the humoral fluid.

[0020] In another embodiment, the present disclosure provides for chimera protein comprising SpyCatcher2 conjugated to Apex2. In one aspect, the chimera protein comprises amino acid SEQ ID NO: 2. In another aspect, the chimera protein is encoded by a DNA sequence comprising SEQ ID NO: 1 . In another embodiment, the present disclosure provides for a DNA sequence encoding for the chimera protein of the present disclosure. In one aspect, the DNA sequence of claim 16, wherein the DNA sequence comprises SEQ ID NO: 1 .

[0021] BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The following figures illustrate various aspects and preferred and alternative embodiments.

[0023] Fig. 1 : Schematic representation of the CFDB workflow. In the presented SARS-CoV- 2 CFDB, serum samples are deposited on a nitrocellulose membrane, immobilizing their repertoire of immunoglobulins in defined spots. Then, anti-NP antibodies, if present, will serve as capture probes for the cell-free-produced SpyTag-NP antigen. This is followed by a universal secondary detection step using the SpyCatcher2-Apex2 peroxidase reporter chimera.

[0024] Figs. 2A-2C: Cell-free production of viral antigens. (2A and 2B) EboV (2A) and SARS- CoV-2 (2B) antigens can be efficiently expressed in an E. coli cell-free lysate and specifically recognized by commercial antibodies in a WB assay. (2C) Highly specific detection of cell-free-produced, Spy-tagged SARS-CoV-2 RBD and NP and EBOV RBD by SpyCatcher2-Apex2 using WB. Arrows mark the predicted molecular weight positions of respective antigens.

[0025] Figs. 3A-3B: CFDB on commercially obtained human sera from control or COVID-19 patients. (3A) Blot image representing an anti-SARSCoV-2 NP CFDB on the WHO international reference panel and RayBiotech PosSet serum samples. Samples were spotted in triplicates columnwise and identified by labels. Neg Cont, negative-control sample obtained by pooling all 10 pre-COVID-19 samples from RayBiotech; RB N1 to N10, RayBiotech presumed-negative samples 1 to 10; RB P1 to P20, RayBiotech presumed positive samples 1 to 20. (3B) Graph representing the quantified chemiluminescence signal intensity values for the blot in panel 3A. The negative control was used to set the cutoff value, and all measurements are means of triplicate spots ± standard deviations (SD). Figs. 4A-4B: Independent testing of CFDB on healthy or COVID-19-positive human sera at NML. (4A) Blot image representing an anti-SARS-CoV-2 NP CFDB on 12 COVID-19-negative (N1 to N12) or 12 positive (P1 to P12) patient samples. Sera were spotted in triplicates columnwise, as labeled. (4B) Quantified chemiluminescence signal intensity values from the blot in panel 4A. All measurements are means of triplicate spots ± SD.

[0026] Figs. 5A-5B: Independent testing of CFDB on recombinant-N Protein-vaccinated hamster sera at NML. 5A. Blot image presenting an anti-SARS-CoV-2 NP CFDB on 4 healthy (N1 -4), two SARS-CoV-2-infected positive control (C1 and C2), and 10 NP- vaccinated (P1 -10) hamster sera. Triplicate spots are deposited per sample columnwise. 5B. Quantified chemiluminescence signal intensity values from the blot in 5A, all measurements are the mean of triplicate spots ± SD.

[0027] Figs. 6A-6B: Independent testing of CFDB on SARS-CoV-2-infected hamster sera at NML. 6A. Blot image presenting an anti-SARS-CoV-2 NP CFDB on hamster sera preinfection (dpi 0, n=12), 140 days after infection (dpi 140, n=3), and 5 days after reinfection (dpi 5, n=21 ) with 105 TCID50 of SARS-CoV-2. Each sample is deposited as triplicate spots column-wise, and labelled according to the scheme in the original NML study. 6B. Quantified chemiluminescence signal intensity values from the blot in 6A, all measurements are the mean of triplicate spots ± SD.

[0028] Figs. 7A-7B: 7A. The CFDB master grid template used in this study, and 7B. Representative CDFB nitrocellulose membrane and master grid set-up for spotting of serum samples.

[0029] Figs. 8A-8K: Cell-free synthetic biology for accelerated screening of different expression / solubility-enhancing tagging variations for viral antigens. 8A: 10 different tagging schemes were applied to 11 individual viral antigens (proteins of interest, POI). The amino acid residue positions for each viral antigen fragment are indicated. 8B-8K: expression constructs were assembled using PCR and added directly to 5 pl cell-free expression reactions. 1 pl of each reaction was run on an SDS-PAGE gel and subjected to Western blot using SpyCatcher2-Apex2 as the detection reagent. Each blot represents expression profiles under one tagging scheme, as indicated, for POIs 1 -11. Red asterisks mark EboV RBD (blot 8B lane 2), SARS-CoV-2 RBD (blot 8B lane 7), and SARS-CoV-2 NP (blot 8C lane 8), for which WB was performed using commercial antibodies against respective antigens (related to Figs. 2A-2B).

[0030] Figs. 9A-9B: CFDB Validation Using WHO Standard Serum Panel. Panels 9A (blot image) and 9B (graph) show signal linearity across serum dilution range and Immunoglobulin levels.

[0031] DETAILED DISCLOSURE

[0032] Definitions

[0033] In this specification and in the claims that follow, reference will be made to several terms that shall be defined to have the meanings below. All numerical designations, e.g., dimensions and weight, including ranges, are approximations that typically may be varied ( + ) or ( - ) by increments of 0.1 , 1.0, or 10.0, as appropriate. All numerical designations may be understood as preceded by the term “about”.

[0034] The term “about,” particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.

[0035] The term “antigen” refers to a substance that causes the immune system of a subject to produce antibodies against it. Antigen includes chemical, bacterial, viral, fungal, plant (such as pollen) and animal antigens.

[0036] “Solid Support” refers to a membrane or a surface suitable for protein immobilization. Non-limiting examples of solid supports include blotting membranes such as nitrocellulose and PDVF (polyvinylidene fluoride) membranes or solid supports such as functionalized glass or plastic slides or beads.

[0037] A “cell free protein synthesis (CFPS)” reaction mixture typically contains a crude or partially-purified eukaryote or bacterial (such as HeLa, CHO, Tobacco, Wheat Germ, E. coli, V. nat., S. subtillis) extract, a DNA or RNA translation template, and a suitable reaction buffer for promoting cell-free protein synthesis from the DNA or RNA translation template. In some aspects, the CFPS reaction mixture can include exogenous RNA translation template. In other aspects, the CFPS reaction mixture can include a DNA expression template encoding an open reading frame operably linked to a promoter element for a DNA-dependent RNA polymerase. In these other aspects, the CFPS reaction mixture can also include a DNA-dependent RNA polymerase to direct transcription of an RNA translation template encoding the open reading frame. In these other aspects, additional NTP's and divalent cation cofactor can be included in the CFPS reaction mixture. A reaction mixture is referred to as complete if it contains all reagents necessary to enable the reaction, and incomplete if it contains only a subset of the necessary reagents. It will be understood by one of ordinary skill in the art that reaction components are routinely stored as separate solutions, each containing a subset of the total components, for reasons of convenience, storage stability, or to allow for application-dependent adjustment of the component concentrations, and that reaction components are combined prior to the reaction to create a complete reaction mixture. Furthermore, it will be understood by one of ordinary skill in the art that reaction components are packaged separately for commercialization and that useful commercial kits may contain any subset of the reaction components of the disclosure.

[0038] “Humor” or “humoral fluid” refers to any bodily fluid containing antibodies, including saliva, tears, mucus, breast milk, intestinal fluid, serum, plasma, blood, vitreous fluid, and so forth.

[0039] Overview

[0040] The present disclosure relates to an immunoassay platform or assay in which humoral fluid, bodily fluids containing antibodies, is used as the immobilized stationary phase of the immunoassay platform. The humoral fluid is directly spotted on solid support, without the need for a physical barrier (i.e., wells) between spots, to immobilize antibodies within the humoral fluid. Antigens are used to probe the humoral fluid on the blotting membrane for detection of an antibody response.

[0041] In one embodiment, the present disclosure relates to an immunoassay framework to detect an antibody of interest in a humoral fluid, where the antibody serves as the immobilized phase, while an antigen or antigens to the antibody of interest serves as the mobile phase. In one embodiment, the antigen to detect the antibody of interest is provided as a hybrid protein in which the antigen is fused to a primary detection tag (“fused antigen”). The fused antigen can be synthesized on demand, or it can be stored, lyophilized, etc. for future use.

[0042] The fused antigen can be synthesized on cell-free protein synthesis, or it can be purified from any other conventional expression system. Advantages of using the cell- free synthetic biology include reducing the cost and time of synthesis for urgent or high throughput assays.

[0043] In one embodiment, the present disclosure relates to a Cell-Free Dot Blot (CFDB) technique, a serological immunoassay framework based on cell-free synthetic biology and alternative dot blot principles where antigens can be synthesized fused to a primary detection tag on-demand and in vitro, then used directly to probe humoral fluid immobilized on a blotting membrane for the detection of an antibody response.

[0044] In one embodiment, the antigen used to probe the humoral fluid is provided as a hybrid protein in which the antigen is fused to a primary detection tag (“primary tag”). The primary tag may be fused to the N-terminus, to the C-terminus or to both the N- terminus and the C-terminus, or internally of the antigen protein. The hybrid protein is then used directly as a primary detection reagent to probe the humoral fluid immobilized on the solid support. A secondary detection reagent is then used to detect whether the antigen in the hybrid protein is attached to an antibody of interest in the humoral fluid. In one embodiment of the present disclosure, the primary tag is a SpyTag peptide (29). In another embodiment, the secondary detection reagent comprises a SpyCatcher peptide.

[0045] In one embodiment of the present disclosure, a method of detecting an antibody in humoral fluid comprises: i) providing a hybrid protein of an antigen fused toa primary tag (in the Examples below the SARS-CoV-2 Nucleocapsid (N) protein containing a universal terminal SpyTag peptide (29)), and used directly (without purification) as primary detection reagent; ii) providing a secondary detection reagent capable of specifically attaching to the primary tag (in the Examples below SpyCatcher-2 (31 ) conjugated to the Apex-2 peroxidase (32) (SpyCatcher-Apex), which in one embodiment is produced by conventional E. co / / -based expression or any other suitable expression vector, is used as a universal secondary detection reagent); iii) humoral fluid from a subject (in the Examples below serum samples (< 0.4 pl)) are spotted and immobilized directly on a blotting membrane, without the need for a physical barrier ( / .e. wells) between spots, and the immobilized antibodies (if present) serve as a capture probe for the provided hybrid protein (see Fig. 1 ).

[0046] In one embodiment, the hybrid protein is produced from a linear deoxyribonucleic acid (DNA) template in a cell-free expression reaction (30), and used directly (without purification) as the primary detection reagent.

[0047] As such, in one embodiment, the present disclosure provides for a method of detecting an antibody of interest in a humoral fluid. In one embodiment, the method comprises, alternatively consist of, alternatively consists essentially of, the following steps: (a) spotting humoral fluid from a subject directly on a solid support thereby immobilizing antibodies within the humoral fluid directly onto the solid support (“spotted solid support”); (b) contacting the spotted solid support with a fusion protein comprising an antigen of the antibody of interest and a primary tag such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen; (c) contacting the spotted solid support contacted with the fusion protein with a secondary detection reagent conjugated to a detectable label, the secondary detection reagent having affinity for the primary tag of the fusion protein to form a complex; and (d) detecting presence of a signal from the detectable label. A presence of the signal from the detectable label indicates the presence of the antibody of interest in the humoral fluid.

[0048] In one embodiment of the method, the primary tag and the secondary detection reagent comprise a Spytag (or a SpyTag-sequence-specific nickel-assisted cleavage tag (SpyTag-SNAC tag)) and SpyCatcher; or Isopeptag and pilin-C; or SnoopTag and SnoopCatcher; or DogTag and SnoopTagJr; or SdyTag and SdyCatcher, or any other affinity tag binding pair.

[0049] In one embodiment, the secondary detection reagent comprises, consists essentially of, or consists of SpyCatcher2 fused to Apex2.

[0050] In one embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the secondary detection reagent is conjugated to a peroxidase, and wherein step (d) comprises (i) contacting the blotting membrane to a solution comprising hydrogen peroxide (H2O2) and at least one readout substrate, wherein the at least one readout substrate can be converted to a readout product in the presence of the H2O2, and (ii) detecting the presence of the readout product. In one aspect the peroxidase is Apex2 or HRP.

[0051] In another embodiment of the method of detecting an antibody of interest in a humoral fluid of the present disclosure, the secondary reagent is conjugated to a reporter that does not require exogenous hydrogen peroxide (for example a fluorescent or colorimetric reporter), in one embodiment, the secondary reagent, such as SpyCatcher, is fluorescently tagged (e.g., by Alexa or GFP) or use fluorescent APEX substrates or use chromogenic / colorimetric SpyCatcher-enzyme pairs (LacZ or Alkaline phosphatase).

[0052] In another embodiment, the present disclosure provides for a SpyCatcher2-Apex2 chimera protein. In one embodiment the SpyCatcher2-Apex2 chimera protein comprises, or consists essentially of, or consists of SEQ ID NO: 2. In another embodiment, the present disclosure relates to a DNA sequence that encodes the SpyCatcher2-Apex2 chimeral protein of the present disclosure. In one aspect, the DNA sequence encoding for the SpyCatcher2-Apex 2 chimera protein of the present disclosure comprises, or consists essentially of, or consists of SEQ ID NO: 2.

[0053] Protein-protein interactions can be diagnostic of disease states (cancer, etc.), and in the case of drug trials / patient monitoring, there may be interactions pairs that could be of interest to the scientific community. As such, in another embodiment, the present disclosure relates to an immunoassay framework for detecting a protein or peptide of interest in a bodily fluid. The protein or peptide of interest includes an antibody, an antigen, a receptor, a hormone and so forth. In one embodiment, a method of detecting a protein or peptide of interest in a bodily fluid comprises, alternatively consist of, alternatively consists essentially of, the following steps: (a) spotting the bodily fluid from a subject directly on a solid support thereby immobilizing proteins and / or peptides within the bodily fluid directly onto the solid support (“spotted solid support”); (b) contacting the spotted solid support with a fusion protein comprising a ligand to the protein of interest and a primary tag such that if the protein of interest is present in the bodily fluid it serves as a capture probe for the ligand; (c) contacting the spotted solid support contacted with the fusion protein with a secondary detection reagent conjugated to a detectable label, the secondary detection reagent having affinity for the primary tag of the fusion protein to form a complex; and (d) detecting presence of a signal from the detectable label, wherein presence of the signal from the detectable label indicates the presence of the protein or peptide of interest in the humoral fluid.

[0054] Kit

[0055] In another embodiment, the present disclosure provides for a kit for detecting an antibody of interest in a humoral fluid comprising: (a) a solid support for immobilizing antibodies in the humoral fluid; (b) a fusion protein comprising an antigen of the antibody of interest and a primary tag; (c) a secondary detection reagent conjugated to a detectable label; and (d) instructions for detecting the antibody of interest. The instructions can comprise any of the methods for detecting an antibody of interest disclosed herein. In one embodiment, the instructions comprise: (i) spotting the humoral fluid from a subject directly on the solid support thereby immobilizing antibodies within the humoral fluid directly onto the blotting membrane (“spotted solid support”); (ii) contacting the spotted solid support with the fusion protein such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen; (iii) contacting the solid support contacted with the fusion protein with the secondary detection reagent conjugated to the detectable label; and (iv) detecting presence of a signal from the detectable label, wherein presence of the signal from the detectable label indicates the presence of the antibody of interest in the humoral fluid.

[0056] In order to aid in the understanding and preparation of the present disclosure, the following illustrative, non-limiting examples are provided.

[0057] EXAMPLES

[0058] Materials and Methods

[0059] Serum samples. Initially, 35 human serum samples were commercially obtained: 5 samples from the first WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20 / 268) (36), consisting of one negative (pre-Covid-19) and 4 positive samples of varying immunoglobulin levels as confirmed by extensive ELISA analyses; and 30 samples from RayBiotech (CoV-PosSet), consisting of 10 negative (pre-Covid-19) and 20 SARS-CoV-2 positive patient samples pre-confirmed positive by at least one of these methods: reverse-transcriptase polymerase chain reaction (RT-PCR), antigen or antibody serology tests. The vendor supplied individual sample details (including days post symptom onset (dpso), testing method, and serology results) for are provided in Tables 2a and 2b.

[0060] For independent testing of the CFDB immunoassay at the NML, 24 human patient sera were provided by the Field Studies group at the NML, including 12 negative and 12 SARS-CoV-2 positive samples. Additionally, two groups of hamster sera were used: one group from a SARS-CoV-2 N protein vaccine candidate efficacy study, and the other group from a SARS-CoV-2 infection study. From the vaccine candidate efficacy study, serum from 4 control hamsters (2 doses of PBS given intramuscularly) was used along with serum from 10 hamsters vaccinated with two doses of 100 ug of recombinant SARS-CoV-2 N protein expressed in a baculovirus expression system, diluted in 1 :5 in emulsigen adjuvant 28 days apart. Serum was collected 21 days following the second vaccine dose. From the SARS-CoV-2 infection study (37), serum from 38 hamsters consisting of 12 pre-infection and 26 post-infection samples were used. For this portion, hamsters were initially infected with 105TCID50 (Median Tissue Culture Infectious Dose) of SARS-CoV-2 (Canada / ON-VIDO-01 / 2020) intranasally and were kept until 140 days post-infection before being challenged again with the same virus. Serum samples taken at day 140 post-infection and on day 5 post-re- infection were used here in our experiment. All samples tested at the NML have been characterized by standard in-house ELISA (Table 3).

[0061] Ethics Statement. All Hamster experiments were carried out at the National Microbiology Laboratory (NML) at the Public Health Agency of Canada, approved by the Canadian Science Centre for Human and Animal Health Animal Care Committee, and performed following the Canadian Council of Animal Care guidelines. All work with infectious virus was performed under biosafety level 4 (BSL-4) conditions. Serum from SARS-CoV-2 infected hamsters was removed from CL-4 following gamma irradiation with 2 MRads.

[0062] Bacterial strains and plasmids. E. coli BL21 (C2530), BL21 (DE3) (C2527) and 5- alpha (C2987) were purchased from New England Biolabs (NEB). pET24b- SpyCatcher2-Apex2 was constructed by cloning the SpyCatcher2 gene between the V5 tag and the first Glycine residue of Apex2 in pET24b-Apex2 (Addgene Plasmid #111702); using NEBuilder® HiFi DNA Assembly Master Mix (E2621 ) and standard molecular cloning procedures in NEB 5-alpha.

[0063] Linear DNA templates for cell-free expression. Linear DNA templates (LETs) coding for viral antigens (with different solubility / expression-enhancing tagging variations) were designed for expression under a T7 promoter and contained terminal Ter sites with 50 base pairs of buffer sequence upstream of the T7 promoter and downstream of the stop codon (See (30) for information on the Tus-Ter linear DNA protection method). All sequences contained a C or N terminal Hise-SpyTag for detection. DNA sequences were synthesised as Gene Fragments by Twist Bioscience and PCR amplified using primers against the Ter sequences. Q5® High-Fidelity DNA Polymerase (NEB M0491 ) was used for all PCRs. PCR reactions were assembled in 100 pl volumes and contained 1x Q5® reaction buffer, 200 pM dNTPs, 500 nM each of forward and reverse primers, 10 ng of Gene Fragments as template, and 1 pl (2 II) of Q5® Polymerase. An Applied Biosystems ProFlex™ thermocycler was used for PCR, cycling on 30 seconds initial denaturation at 98°C; followed by x35 cycles of 6 second at 98°C, 15 seconds at 60°C, and 90 seconds at 72°C. For initial WB screening, crude PCR products were added directly to cell-free reactions, but if intended for CFDB, PCR products were purified before cell-free expression using the QIAquick PCR Purification Kit (Qiagen #28106). PCR quality was confirmed by agarose gel electrophoresis. Gene Fragment sequences are provided in Table 4.

[0064] Cell-free lysate preparation and reaction set-up. E. coli BL21 -based cell-free lysates and expression reactions were prepared as described in Norouzi et. al. (30). Reactions contained a final concentration of 5 pM of the Tus protein and 1 .2 pM of T7 RNA Polymerase, and were incubated at 30 °C for 15 hours. For initial WB screening experiments, cell-free reactions were assembled in 5 pl final volumes in PCR tubes and contained 10 % v / v of crude PCR mixes for LETs. To express the SARS-CoV-2 Nucleocapsid protein for CFDB experiments, cell-free reactions were assembled in 1 ml final volumes in 15 ml Falcon tubes and contained 15 nM of purified LET, and were incubated with gentle shaking at 80 RPM. Completed reactions were aliquoted and stored at -20 °C until use. Since all LETs encoded a SpyTag, cell-free expression profiles of antigens were visualised by WB using the SpyCatcher2-Apex2 peroxidase conjugate. Briefly, 1 pl of each reaction was run on a 12 % Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, and transferred using a TransBlot® Turbo™ Transfer System (BioRad) to a Nitrocellulose membrane. Blocking and detection steps were performed as described below for the CFDB blocking and secondary detection procedures.

[0065] SpyCatcher2-Apex2 expression and purification. Bacterial culture media always contained 50 pg / ml of kanamycin. pET24b-SpyCatcher2-Apex2 was transformed into BL21 (DE3) cells and grown on an agar plate. Next day, a single colony was inoculated into 15 ml of Lysogeny Broth (LB) media and incubated overnight at 37 °C. 10 ml of this starter culture was used to inoculate 500 ml of fresh LB culture growing at 37 °C, with shaking at 250 RPM. When the cells reached mid-exponential phase (OD600= ~ 0.8), SpyCatcher2-Apex2 expression was induced by the addition of 0.5 mM Isopropyl (3-D-1 -thiogalactopyranoside (IPTG) and 1 mM 5-Aminolevulinic acid hydrochloride (Sigma-Aldrich), and growth temperature was reduced to 30 °C. Four hours after induction, cells were harvested by centrifugation at 8000 x g for 15 minutes, and the pellet was kept at -80 °C until use.

[0066] To purify SpyCatcher2-Apex2, the cell pellet was resuspended in 20 ml of lysis buffer containing: 50 mM Tris-HCI (PH 7.8), 300 mM NaCI, one complete™ EDTA-free Protease Inhibitor tablet, 1 mM Dithiothreitol (DTT) and 100 pg / ml Lysozyme. To lyse the cells, sonication was performed on a Fisherbrand™ Q700 sonicator at 50 % amplitude, 5 seconds ON cycles for a total of 3 minutes, with 10 seconds OFF intervals. To clarify the lysate, centrifugation was performed on an Avanti JXN-30 Series centrifuge (Beckman Coulter) at 20,000 x g for 1 hour at 4 °C, and the supernatant was passed through a 0.2 pm Basix™ syringe filter. To maximize heme incorporation in the Apex-2 peroxidase, Hemin Chloride (Sigma-Aldrich H9039) was added to the clarified lysate to a final concentration of 250 pM, and the mixture was kept overnight at 4 °C.

[0067] The next day, 2.5 ml of NEBExpress® Ni Resin was added to 20 ml of the clarified lysate and incubated with shaking at 4 °C for 45 minutes. The resin-bound protein was purified by applying the mixture to a gravity flow column, followed by a 50 ml wash with Tris buffer (50 mM Tris-HCI (PH 7.8), 300 mM NaCI, 1 mM DTT). SpyCatcher2- Apex2 was then eluted by adding 25 ml of the Tris buffer containing 400 mM Imidazole. The eluted protein was concentrated and buffer-exchanged into Tris buffer using an Amicon® Ultra-15 centrifugal filter unit. Final protein concentration was determined using the molar extinction coefficient of SpyCatcher2-Apex2 (s= 27390 M’1cnr1) on a Thermo Scientific™ NanoDrop™ One UV-Vis Spectrophotometer. For storage, glycerol was added to 40 % (storage buffer: 50 mM Tris-HCI (PH 7.8), 300 mM NaCI, 1 mM DTT, 40 % glycerol) and aliquots (here at 20 mg / ml) were stored at -20 °C. This expression-purification method yields ~40 mg of highly (>95 %) pure SpyCatcher2- Apex2 (SEQ ID NO: 1 ) from a 500 ml starting LB culture (sufficient for ~400 x 96 sample CFDBs).

[0068] Cell-free dot blot procedure. Bio-Rad's 0.2 pm pore-size nitrocellulose (NC) membrane with a 80-100 pg / cm2protein binding capacity was used for dot blot experiments. To facilitate spotting and analysis, a 6 x 6 cm master grid pattern containing 12 x 12 circles of 2 mm diameter, was designed in Microsoft PowerPoint and printed on an A4 paper. We typically use the bordering rows to mark the NC membrane boundaries and allow a 100-spot capacity (similar to a 96 well plate) per blot. The printed grid was cut to size and sandwiched between two clear plastic sealing films (SARSTEDT), and the marked circles were excised using a 2 mm Integra™ Miltex™ Biopsy Punch. This way, the master grid can be reused multiple times, wiping with 70 % Ethanol after each experiment. A copy of the master grid and a photograph of a typical NC membrane set-up are provided in Fig. 7.

[0069] To perform the dot blot protocol, a ~ 6 x 6 cm piece of NC membrane was cut and placed under the master grid on a flat surface, fixing the membrane-grid in place using stationary tape around edges and marking the boundary wells with a marker pen as needed. The serum samples were first diluted 1 / 10 in 1x Phosphate Buffered Saline (PBS) PH 7.4. Then, using a micro-pipette tip, 0.4 pl of each sample was dispensed in triplicates onto individual circles / wells. It typically takes one person 20-30 minutes to dispense a full blot of 100 spots. Blots were left for 10 minutes to dry / bind, and the NC membrane was gently removed and further cut along the marked boundaries (typically ~5 x 5 cm for a full 100-spot blot). Membranes were blocked for 30 minutes in 10 ml of Blocking Solution (1x Tris Buffered Saline (Fisher)-0.05 % Tween-20 (TBST) containing 5 % non-fat dry milk) with shaking (100 RPM) at room temperature. We typically use 10 cm petri dishes for membrane blocking and incubation steps.

[0070] For antigen binding (primary detection step), 50 pl of the N protein cell-free reaction mix was added to 5 ml of Blocking Solution and incubated with the NC membrane for 1 hour with shaking at 100 RPM. The membrane was then rinsed, washed for 5 minutes, and rinsed again in fresh TBST. For secondary detection step, 5 pl (100 pg) of the purified SpyCartcher2-Apex2 protein was added to 10 ml of Blocking Solution and incubated with the membrane for 1 hour with shaking at 100 RPM. The membrane was rinsed and washed twice for 5 minutes each time in fresh TBST, and rinsed again in fresh TBS. The membrane was then incubated for 90 seconds with 3 ml (~ 0.1 ml / cm2) of enhanced chemiluminescence (ECL) solution. We used a home-made ECL mixture based on the recipe provided in (38), containing final concentrations of 0.4 mM p-Coumaric acid, 2.5 mM Luminol, and 0.015 % H2O2, in 100 mM Tris-HCI (PH 8.6). Blot imaging was performed using a BioRad ChemiDoc XRS+ (UotT) or an Azure Biosystems gel imager (NML) on default acquisition settings. We note that in the images acquired by the Azure Biosystems gel imager (Figures 4A, 5A and 6A) the appearance of vertical lines in the blots is a result of image-quality artifacts introduced by the imaging equipment rather than splicing.

[0071] Data analysis. Spot intensity data were measured using the Volume Tool in Image Lab Software (BioRad). Measurements were performed by first subtracting NC membrane background, and then subtracting negative control sample intensities from all spots. A cut-off value was set according to (13) and as follows: (mean of negative controls) + (3 x standard deviation of the negative controls). A sample was considered positive if its intensity was higher than the cut-off value. Data were plotted using the GraphPad Prism Software.

[0072] Results

[0073] Cell-free production of viral antigens. Linear DNA fragments were designed encoding different solubility / expression-enhancing tagging variations for viral antigens, all encoding an N or C terminal Hise-SpyTag. A full list of tested viral antigens and tagging variations, and representative WB expression profile images are provided in Fig. 8. We selected candidate versions of viral antigens representing the SARS- CoV-2 Nucleocapsid protein, as well as Receptor Binding Domains (RBD) of the Surface Glycoproteins of EboV and SARS-CoV-2. We then evaluated the successful cell-free expression of these antigens by WB using commercial antibodies (SinoBiological — Rabbit polyclonal) raised against respective viral antigens. As shown in Figs. 2A and 2B, cell-free produced viral antigens can be specifically recognised by mammalian antibodies, confirming the proper epitope presentation of EboV and SARS-CoV-2 antigens respectively, and highlighting their potential for use in immunoassays. We also determined that for the SARS-CoV-2 Nucleocapsid protein, the N-terminally Hise-SpyTagged version was the best-expressing tagging design and took this sequence forward for CFDB experiments.

[0074] SpyCatcher2-Apex2 as a secondary detection reagent. The efficient, irreversible isopeptide bond formation mechanism between SpyCatcher-SpyTag has been extensively elucidated before (39). The robust performance of the Apex-2 peroxidase has also been demonstrated (32, 40). Given that both proteins express efficiently in conventional E. co / / -based systems, we hypothesized that a SpyCatcher2-Apex2 chimera would represent a unique and low-cost alternative to commercial secondary detection reagents (e.g. Horseradish Peroxidase antibody conjugates) that can be produced in-house. Indeed, to analyse the cell-free expression profiles of our Spy- Tagged viral antigens we performed WB using the SpyCatcher2-Apex2 protein, demonstrating that this tagging system provides for highly specific and robust detection of target proteins Fig. 2C.

[0075] Covid-19 CFDB immunoassay on commercial human sera. We first established the feasibility of CFDB as a Covid-19 immunoassay using standard, pre-characterised human sera. Therefore, we acquired Covid-19 serum samples from two sources: from NISBC — the WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin containing 1 x pre-Covid-19 and 4 x SARS-Cov-2 positive samples; and from RayBiotech — CoV-PosSet containing 10 x pre-Covid-19 and 20 x SARS- Cov-2 positive samples. The NISBC samples have been extensively pre-characterised and validated using a variety of standard ELISA tests and contain very low to very high anti-SARS CoV-2 immunoglobulin levels (36) Table 2. The CoV-PosSet on the other hand, has been tested using different methods and shown to be positive by at least one method including: PCR, antigen, ELISA (for anti-S1 RBD IgG and IgM), and LFA (anti-N IgG and IgM) Table 2. Interestingly, in the provided immunoassay information, three (by anti-S1 RBD IgG ELISA) and twelve (by anti-N IgG / M LFA) samples, out of the total 20 Covid-19-positive samples, had antibody levels below the detection capacity of the respective immunoassays.

[0076] We first optimised the serum dilution factor and found that a 1 / 10 (in PBS) dilution nears the NC membrane’s protein binding capacity (41 ) — enabling broader representation of the immunoglobulin repertoire; and yields higher signal to noise ratios, as has been shown in other studies (42). We also found that for increased reliability, a Negative Control must be a pooled mixture of multiple negative samples to account for residual background signal in individual samples (13). Therefore, we pooled the 10 pre-Covid-19 samples from RayBiotech as Negative Control, and used the NISBC’s (#High IgG) as Positive Control.

[0077] As shown in Figs. 3A and 3B, our Covid-19 CFDB immunoassay correctly identified all 5 samples from the WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin. In addition, for RayBiotech’s CoV-PosSet, CFDB correctly discriminated all 10 pre-Covid-19 sera from 18 out of 20 Covid-19-positive samples. The only 2 presumed positive samples that were not detected by the CFDB assay were samples #15 (dpso 34) and #20 (dpso 4) (RB P5 and RB P10 respectively in Fig. 3), which, importantly, also appear negative in RayBiotech’s datasheet for anti-S1 RBD IgG by ELISA and anti-N IgG / M by LFA. Suggesting that these two samples also have immunoglobulin levels below the detection capacity of CFDB.

[0078] Independent testing of the Covid-19 CFDB immunoassay (NML). Having established the feasibility of the CFDB framework as an efficient serological immunoassay, we examined the performance of our Covid-19 CFDB in an independent setting. To this end, we prepared and shipped a kit containing all necessary assay reagents and instructions to our collaborators in the NML. An advantage of this collaboration was that NML has a long track-record of vaccine development studies, and therefore would be an ideal setting to assess the performance of our serological immunoassay against standard ELISA procedures. At NML, we performed CFDB on pre-characterised sera from three different sources: i) human Covid-19 patient sera; ii) Recombinant N Protein -vaccinated hamster sera; and iii) SARS-CoV-2-infected hamster sera.

[0079] Covid-19 CFDB immunoassay on human patient sera. As part of the independent evaluation of CFDB, we tested a set of 24 human sera from 12 healthy, and 12 Covid- 19 positive patients verified by ELISA to be positive for anti-N protein antibodies. As shown in Figs. 4A-4B, CFDB successfully detected anti-N protein antibodies in the 12 Covid-19 positive sera and, as expected, not in sera from healthy patients. This further demonstrates the potential of CFDB as a practical immunoassay platform for community screening.

[0080] Covid-19 CFDB immunoassay on Recombinant-N Protein-vaccinated hamster sera. A common practice in vaccine development studies is the administration of recombinantly produced antigens to animal models to induce antibody production (43). Standard ELISA immunoassays are an integral part of this process as they can assess the presence or absence of an antibody response. Encouraged by our results with human sera, we reasoned that CFDB can also be a more accessible alternative to ELISA in such animal model studies. As proof of principle, we subjected 14 hamster sera from a baculovirus-produced SARS-CoV-2 N Protein vaccine candidate efficacy study, and two positive control samples from SARS-CoV-2-infected hamsters (taken 5 days after re-infection on dpi 140), to our CFDB immunoassay. Of the 14 animals, 4 hamsters had been treated with PBS alone, and 10 hamsters had been vaccinated with recombinant N Protein in emulsigen adjuvant, collecting serum samples at 3 weeks following a second dose. As above, the CFDB results correctly distinguished all 12 positive hamster sera (2 SARS-CoV-2-infected, and 10 N Protein-vaccinated) from the 4 negative sera (see Figs. 5A and 5B).

[0081] Covid-19 CFDB immunoassay on SARS-CoV-2-infected hamster sera. Detection and management of infectious diseases in animal populations is of critical importance both economically and from a wildlife preservation perspective (44). To demonstrate its potential as a veterinary immunoassay, we performed CFDB on sera obtained from SARS-CoV-2-infected hamster sera. In this experiment we tested 36 samples; 12 preinfection (dpi 0) and 24 post infection samples. Here animals were infected with 105TCID50 of SARS-CoV-2 and left until dpi 140 (n=3), or subsequently re-challenged with the same virus and euthanized at dpi 5 (n=21 ). As expected, no signal above background levels was observed in the pre-infection sera, and the majority (n=18) of post-infection sera, all 5 days post-re-infection, produced discrete positive signals (see Figs. 6A and 6B). Interestingly in this assay, 3 samples from 5 days post-re-challenge and all 3 samples from the initial dpi 140 did not produce a positive signal. This result is partly corroborated with an anti-N Protein ELISA assay performed on the same sample set (using commercial SARS-CoV-2 antigen), where no positive signal was observed for samples from dpi 140 (Table 3), suggesting that the antibody response may have waned over time (45).

[0082] The present disclosure describes a serological immunoassay that utilizes the principles of cell-free synthetic biology and based on an alternative dot blot concept (CFDB) where antibodies (and not the antigens) are immobilized in a solid phase. This combination confers novel and unique capabilities to CFDB of the present disclosure compared to conventional immunoassay platforms such as ELISAs or LFAs. Notably, CFDB reagents can be rapidly produced using minimal resources at decentralized laboratories, without reliance on potentially strained or inaccessible commercial supplies. In addition, CFDB of the present disclosure follows a similar detection workflow to the widespread WB technique, facilitating adoption in most research and clinical diagnostic laboratories worldwide. The use of linear cell-free expression templates enables interchangeable testing of multiple pathogenic antigens, for rapid repurposing of the assay towards new pathogens. The chimeric SpyCatcher2-Apex2 universal detection reagent, efficiently produced in an E. coli expression system, provides a low-cost replacement for commercial secondary antibody conjugates. Furthermore, a regular, unaltered nitrocellulose membrane provides scalable throughput similar to 96-well ELISA plates, without the need for a physical barrier between serum samples. Strikingly, the calculated cost for one CFDB assay kit of the present disclosure is only ~$3 USD (Table 1 ), a small fraction of commercial 96-well ELISA assay kits at >$300 USD.

[0083] To demonstrate the feasibility of the novel immunoassay presented herein, we performed CFDB on pre-validated sera from Covid-19 negative and positive subjects in two steps. First, we tested 35 commercially obtained samples comprising 5 samples from the first WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (1 control and 4 Covid-19 positive), and 30 samples from RayBiotech (CoV-PosSet, 10 control, and 20 Covid-19 positive). Here, our Covid-19 CFDB immunoassay correctly identified all 11 negative samples and yielded a positive signal in 22 out of 24 presumed positive samples (Figs. 3A and 3B). While the 2 missed presumed positive samples also appear negative in RayBiotech’s datasheet for anti- S1 RBD IgG and anti-N IgG / M immunoassays.

[0084] Second, we prepared and shipped a kit of the present disclosure containing all required Covid-19 CFDB reagents to our collaborators at the NML for independent testing. There, we performed CFDB on three sample sets: 24 human patient sera (12 healthy and 12 Covid-19 positive, Figs. 4A-4B), 14 recombinant N-protein-vaccinated hamster sera (4 control and 10 vaccinated, Figs. 5A-5B), and 38 SARS-CoV-2- infected hamster sera (12 control and 26 infected, Figs. 6A-6B, with two of the infected samples presented in Figs. 5A-5B). In these assays, CFDB correctly diagnosed all samples, apart from 6 Covid-19-infected hamster sera taken 140 days post-challenge or 5 days post-re-challenge — half of which had also given a negative signal in a standard N-protein ELISA. Overall, we have demonstrated that our Covid-19 CFDB immunoassay is capable of highly specific and reasonably sensitive detection of anti- SARS-CoV-2 antibodies in both human and animal sera, with a performance closely matching that of standard ELISA assays. iVral antigens are structurally complex and may, in some cases, be difficult to produce in bacterial-based systems in functionally folded forms (46). However, multiple strategies exist to overcome this issue, including the expression of functional antigenic sub-fragments (47, 48); the use of chaperones and oxidising additives in optimised cell-free lysates (28); and the use of eukaryotic-derived cell-free systems (27, 46, 49). Secondly, the occurrence of visible hemolysis during serum sample preparation may confound CFDB results interpretation due to endogenous peroxidase activity of hemoglobin. This issue equally applies to standard peroxidase-based ELISA assays, and can be prevented by careful sampling practices. And finally, unlike ELISA assays, CFDB measures total antibody response and cannot distinguish between antibody subclasses (i.e. IgA, IgM, IgG). However, for the purposes of decentralized testing, rapid response, and mass screening, antibody subclasses are not of critical importance, and a total antibody measurement can even increase the sensitivity of the assay.

[0085] In conclusion, presented herein is a novel immunoassay, which in embodiments is based on the principles of cell-free synthetic biology and the dot-blot technique. The present platform, termed CFDB, can serve as a practical, deployable, and cost- effective alternative to conventional ELISA assays, especially when surge capacity is needed for pandemic response. In addition, CFDB has the potential for rapid repurposing and adaptation towards other existing and emerging pathogens. CFDB can be rapidly adapted for any number of antigens. CFDB provides additional capacity in clinical and research laboratories, especially in low- and middle-income countries, for serological immunoassays in human and animal populations.

[0086] DNA sequence encoding for SpyCatcher2-Apex2 chimera protein (SEQ ID NO: 1) taatacgactcactataggggaattgtgagcggataacaattcccctctagaaataattttgtttaactttaagaaggag atatacatatgggcaagcccatccccaaccccctgctgggcctggacagcaccGgcgccatggtaaccaccttatc aggtttatcaggtgagcaaggtccgtccggtgatatgacaactgaagaagatagtgctacccatattaaattctcaaaa cgtgatgaggacggccgtgagttagctggtgcaactatggagttgcgtgattcatctggtaaaactattagtacatggat ttcagatggacatgtgaaggatttctacctgtatccaggaaaatatacatttgtcgaaaccgcagcaccagacggttat gaggtagcaactgctattacctttacagttaatgagcaaggtcaggttactgtaaatggcgaagcaactaaaggtgac gctcatactggatccagtggtagcGgaaagtcttacccaactgtgagtgctgattaccaggacgccgttgagaaggc gaagaagaagctcagaggcttcatcgctgagaagagatgcgctcctctaatgctccgtttggcattccactctgctgga acctttgacaagggcacgaagaccggtggacccttcggaaccatcaagcaccctgccgaactggctcacagcgct aacaacggtcttgacatcgctgttaggcttttggagccactcaaggcggagttccctattttgagctacgccgatttctac cagttggctggcgttgttgccgttgaggtcacgggtggacctaaggttccattccaccctggaagagaggacaagcct gagccaccaccagagggtcgcttgcccgatcccactaagggttctgaccatttgagagatgtgtttggcaaagctatg gggcttactgaccaagatatcgttgctctatctgggggtcacactattggagctgcacacaaggagcgttctggatttga gggtccctggacctctaatcctcttattttcgacaactcatacttcacggagttgttgagtggtgagaaggaaggtctcctt cagctaccttctgacaaggctcttttgtctgaccctgtattccgccctctcgttgataaatatgcagcggacgaagatgcct tctttgctgattacgctgaggctcaccaaaagctttccgagcttgggtttgctgatgccctcgagcaccaccaccaccac cactgagatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataactagcat aaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggaggaactatatccggattggcgaatgggac gcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccct agcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctcc ctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccat cgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaac actcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaa caaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttttcggggaaatgtgcgcggaacc cctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaattaattcttagaaaaactcatcgagcatcaaatga aactgcaatttattcatatcaggattatcaataccatatttttgaaaaagccgtttctgtaatgaaggagaaaactcaccg aggcagttccataggatggcaagatcctggtatcggtctgcgattccgactcgtccaacatcaatacaacctattaattt cccctcgtcaaaaataaggttatcaagtgagaaatcaccatgagtgacgactgaatccggtgagaatggcaaaagtt tatgcatttctttccagacttgttcaacaggccagccattacgctcgtcatcaaaatcactcgcatcaaccaaaccgttatt cattcgtgattgcgcctgagcgagacgaaatacgcgatcgctgttaaaaggacaattacaaacaggaatcgaatgc aaccggcgcaggaacactgccagcgcatcaacaatattttcacctgaatcaggatattcttctaatacctggaatgctg ttttcccggggatcgcagtggtgagtaaccatgcatcatcaggagtacggataaaatgcttgatggtcggaagaggca taaattccgtcagccagtttagtctgaccatctcatctgtaacatcattggcaacgctacctttgccatgtttcagaaacaa ctctggcgcatcgggcttcccatacaatcgatagattgtcgcacctgattgcccgacattatcgcgagcccatttatacc catataaatcagcatccatgttggaatttaatcgcggcctagagcaagacgtttcccgttgaatatggctcataacaccc cttgtattactgtttatgtaagcagacagttttattgttcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtca gaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaacc accgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcg cagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacct cgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagtt accggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctaca ccgaactgagatacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtat ccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatagt cctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgc cagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtgg ataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgag cgaggaagcggaagagcgcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcaatggtgcactct cagtacaatctgctctgatgccgcatagttaagccagtatacactccgctatcgctacgtgactgggtcatggctgcgcc ccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtg accgtctccgggagctgcatgtgtcagaggttttcaccgtcatcaccgaaacgcgcgaggcagctgcggtaaagctc atcagcgtggtcgtgaagcgattcacagatgtctgcctgttcatccgcgtccagctcgttgagtttctccagaagcgttaa tgtctggcttctgataaagcgggccatgttaagggcggttttttcctgtttggtcactgatgcctccgtgtaagggggatttct gttcatgggggtaatgataccgatgaaacgagagaggatgctcacgatacgggttactgatgatgaacatgcccggt tactggaacgttgtgagggtaaacaactggcggtatggatgcggcgggaccagagaaaaatcactcagggtcaat gccagcgcttcgttaatacagatgtaggtgttccacagggtagccagcagcatcctgcgatgcagatccggaacata atggtgcagggcgctgacttccgcgtttccagactttacgaaacacggaaaccgaagaccattcatgttgttgctcagg tcgcagacgttttgcagcagcagtcgcttcacgttcgctcgcgtatcggtgattcattctgctaaccagtaaggcaaccc cgccagcctagccgggtcctcaacgacaggagcacgatcatgcgcacccgtggggccgccatgccggcgataat ggcctgcttctcgccgaaacgtttggtggcgggaccagtgacgaaggcttgagcgagggcgtgcaagattccgaat accgcaagcgacaggccgatcatcgtcgcgctccagcgaaagcggtcctcgccgaaaatgacccagagcgctgc cggcacctgtcctacgagttgcatgataaagaagacagtcataagtgcggcgacgatagtcatgccccgcgcccac cggaaggagctgactgggttgaaggctctcaagggcatcggtcgagatcccggtgcctaatgagtgagctaacttac attaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcg cggggagaggcggtttgcgtattgggcgccagggtggtttttcttttcaccagtgagacgggcaacagctgattgccctt caccgcctggccctgagagagttgcagcaagcggtccacgctggtttgccccagcaggcgaaaatcctgtttgatgg tggttaacggcgggatataacatgagctgtcttcggtatcgtcgtatcccactaccgagatatccgcaccaacgcgca gcccggactcggtaatggcgcgcattgcgcccagcgccatctgatcgttggcaaccagcatcgcagtgggaacgat gccctcattcagcatttgcatggtttgttgaaaaccggacatggcactccagtcgccttcccgttccgctatcggctgaatt tgattgcgagtgagatatttatgccagccagccagacgcagacgcgccgagacagaacttaatgggcccgctaaca gcgcgatttgctggtgacccaatgcgaccagatgctccacgcccagtcgcgtaccgtcttcatgggagaaaataata ctgttgatgggtgtctggtcagagacatcaagaaataacgccggaacattagtgcaggcagcttccacagcaatggc atcctggtcatccagcggatagttaatgatcagcccactgacgcgttgcgcgagaagattgtgcaccgccgctttaca ggcttcgacgccgcttcgttctaccatcgacaccaccacgctggcacccagttgatcggcgcgagatttaatcgccgc gacaatttgcgacggcgcgtgcagggccagactggaggtggcaacgccaatcagcaacgactgtttgcccgccag ttgttgtgccacgcggttgggaatgtaattcagctccgccatcgccgcttccactttttcccgcgttttcgcagaaacgtgg ctggcctggttcaccacgcgggaaacggtctgataagagacaccggcatactctgcgacatcgtataacgttactggt ttcacattcaccaccctgaattgactctcttccgggcgctatcatgccataccgcgaaaggttttgcgccattcgatggtgt ccgggatctcgacgctctcccttatgcgactcctgcattaggaagcagcccagtagtaggttgaggccgttgagcacc gccgccgcaaggaatggtgcatgcaaggagatggcgcccaacagtcccccggccacggggcctgccaccatac ccacgccgaaacaagcgctcatgagcccgaagtggcgagcccgatcttccccatcggtgatgtcggcgatataggc gccagcaaccgcacctgtggcgccggtgatgccggccacgatgcgtccggcgtagaggatcgagatctcgatccc gcgaaat

[0087] SpyCatcher2-APEX2 amino acid sequence (SEQ ID NO: 2)

[0088] MGKPIPNPLLGLDSTGAMVTTLSGLSGEQGPSGDMTTEEDSATHIKFSKRDEDGRE LAGATMELRDSSGKTISTWISDGHVKDFYLYPGKYTFVETAAPDGYEVATAITFTVN EQGQVTVNGEATKGDAHTGSSGSGKSYPTVSADYQDAVEKAKKKLRGFIAEKRCA PLMLRLAFHSAGTFDKGTKTGGPFGTIKHPAELAHSANNGLDIAVRLLEPLKAEFPIL SYADFYQLAGWAVEVTGGPKVPFHPGREDKPEPPPEGRLPDPTKGSDHLRDVFG KAMGLTDQDIVALSGGHTIGAAHKERSGFEGPWTSNPLIFDNSYFTELLSGEKEGLL QLPSDKALLSDPVFRPLVDKYAADEDAFFADYAEAHQKLSELGFADALEHHHHHH

[0089] V5 tag (SEQ ID NO: 3)

[0090] GKPIPNPLLGLDST

[0091] SpyCatcher2 (SEQ ID NO: 4) GAMVTTLSGLSGEQGPSGDMTTEEDSATHIKFSKRDEDGRELAGATMELRDSSGK TISTWISDGHVKDFYLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGEATKG DAHTGSSGS APEX2 (SEQ ID NO: 5)

[0092] GAMVTTLSGLSGEQGPSGDMTTEEDSATHIKFSKRDEDGRELAGATMELRDSSGK TISTWISDGHVKDFYLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGEATKG DAHTGSSGS x6 His tag (SEQ ID NO: 6)

[0093] HHHHHH

[0094] Table 1. Cost breakdown for one CFDB assay at equivalent capacity to a 96-well ELISA plate:

[0095] Table 2a: NIBSC WHO Reference Panel

[0096] Table 3. ELISA results for samples processed at NML. Respective sample sets for each figure are indicated. Cut-off value in all cases has been set to zero.

[0097] Table 4

[0098] POI-TEV-His-Spy

[0099] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGCGCGACAAATTAAGCAGCACTAATCAGTTACGCAGTGTCGG ATTGAACCTGGAGGGCAACGGCGTCGCCACAGACGTTCCGTCCGCCACGAAG CGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGGTTGTTAATTATGAAGCTGG TGAATGGGCCGAAAATTGCTACAACTTAGAGATCAAGAAGCCAGACGGTTCAGA GTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGCTTTCCTCGCTGCCGTTATG

[0100] TTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGGTGATTTCGCTTTTCACAAA GAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCAACGGTCATTTACCGCGGG ACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAATTCTGCCCCAAGCTAAGAA G G ATTT CTTCTC GT C AC AT C CTCTTC GT G AG Gattacgacatcccaacgaccgaaaacctgtat tttcagggcTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACCGACTATT

[0101] GTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCTAActcgagccttaggagat ccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0102] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGATTCCTTTAGGTGTAATCCACAATAGCACACTTCAGGTAAGT

[0103] GACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCTAGTACTAACCAACTGCGTT CTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGCCACGGATGTCCCGTCGGCA ACGAAACGCTGGGGATTTCGCTCTGGAGTGCCGCCTAAAGTGGTCAACTATGA AGCAGGCGAGTGGGCGGAGAATTGTTACAATTTAGAGATTAAAAAACCAGACG GGTCTGAGTGCTTACCTGCCGCGCCCGACGGTATCCGCGGATTTCCACGCTGT

[0104] CGCTATGTGCACAAAGTTAGTGGTACTGGTCCGTGTGCAGGGGATTTCGCATTT CACAAAGAAGGAGCCTTCTTTCTTTATGATCGTCTTGCTTCCACCGTAATTTACC GTGGCACGACGTTTGCTGAGGGGGTGGTAGCGTTCCTGATCCTGCCGCAAGCA AAAAAGGACTTTGattacgacatcccaacgaccgaaaacctgtattttcagggcTCAGGCGGTCAT CATCATCACCACCATAGTGGTTCCGTACCGACTATTGTAATGGTTGATGCATAC

[0105] AAACGCTACAAAGGAAGTGGCTAActcgagccttaggagatccggctgctaacaaagcccgaaag gaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0106] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTTAAGTTCCACTAACCAGCTTCGTAGTGTAGGGTTAAACTTG

[0107] GAAGGTAACGGAGTAGCTACGGATGTGCCTAGCGCTACGAAGCGTTGGGGGTT TCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTACGAAGCAGGCGAATGGGCAG AAAATTGCTATAATCTGGAAATTAAAAAGCCTGACGGCAGCGAATGTTTACCTG CCGCCCCGGACGGCATCCGTGGATTTCCACGTTGTCGCTACGTGCATAAGGTA

[0108] TCAGGCACCGGCCCTTGTGCGGGTGattacgacatcccaacgaccgaaaacctgtattttcagggc TCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACCGACTATTGTAATG GTTGATGCATACAAACGCTACAAAGGAAGTGGCTAActcgagccttaggagatccggctgct aacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0109] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGGAAGCCATCGTGAACGCCCAACCCAAATGTAATCCAAATCT GCATTATTGGACAACACAAGATGAAGGGGCAGCTATCGGCTTAGCCTGGATTC CGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTGAAGGCCTGATGCACAAT

[0110] CAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCCAACGAAACTACTCAAGC CTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGTACATTCTCAATCTTAAA

[0111] CCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGAGGTACGTGCCACATTTT AGGTCCTGACTGCTGTATTGAACCACACGATTGGACTAAGAATATTACGGACAA GATCGACCAGATTATTCATGATTTTGTTGATAAGACGTTACCGGATCAGGGTGA CAATGATAATTGGTGGACGGGCTGGCGTGattacgacatcccaacgaccgaaaacctgtattttc agggcTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACCGACTATTGT

[0112] AAT G GTT GAT G CAT AC AAAC G CTAC AAAG G AAGT G G CTAActcgagccttaggagatccg gctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0113] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGGAAGCCAAACCCAGTGGAAGCGTCGTGGAACAGGCAGAAG

[0114] GTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGACACCCCCGCAAGTGTAT AACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAATCTTACCAAATTGCTGTC TCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCTCCGGCCGCGATCGCT TCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTTATCCCCTTTCCATGAA AAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTCGCAATTTAACTATAAACA

[0115] GTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACCGTACCTCATAATTTAACG ACGATCACCAAGCCACTGAAGTACAGCTATATTAATAAATGCAGTCGTTTGCTGT CGGACGACCGCACGGAAGTACCCCAATTGGTTAATGCGAACCAATACTCTCCC TGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGATGGTGATTACTACCGCAAA CAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGGCAAGTGGTTCTACGGT

[0116] TGCAATGACCGAGCAATTGCAAATGGGCTTCGGCATTACAGTTCAATATGGTAC TGACACGAACAGTGTATGCCCTAAGATTGAATTTGCGAATGACACTAAAATTGC CTCGCAATTAGGAAACTGTGTCGAATATGattacgacatcccaacgaccgaaaacctgtattttca gggcTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACCGACTATTGTA ATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCTAActcgagccttaggagatccgg ctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0117] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTACGTTGATGTCGGTCCAGACTCGGTAAAAAGTGCTTGCATT GAAGTGGACATTCAACAGACCTTCTTCGATAAAACTTGGCCTCGTCCTATCGAT

[0118] GTTAGCAAGGCGGATGGCATCATCTATCCTCAGGGCCGCACATATTCGAACATT ACCATCACATATCAGGGCTTGTTTCCTTACCAAGGCGACCATGGTGATATGTAC GTTTATTCTGCTGGACACGCGACTGGTACTACCCCTCAGAAACTGTTTGTTGCG AACTACTCTCAAGACGTGAAGCAATTTGCGAATGGGTTCGTAGTTCGCATTGGG GCAGCGGCGAACTCAACTGGGACAGTGATTATTTCGCCCAGTACATCGGCGAC GATTCGTAAGATTTATCCAGCCTTCATGTTAGGGTCGTCCGTGGGTAACTTTAG CGACGGGAAGATGGGGCGTTTTTTCAACCACACCCTGGTGTTGTTGCCGGATG GTTGCGGTACCTTACTTCGCGCTTTTTATTGTATTTTAGAGCCCCGCTCTGGTAA CCACTGTCCCGCGGGTAACTCATACACATCTTTTGCCACTTACCACACCCCCGC GACAGACTGCAGCGATGGTAACTATAATCGTAACGCCTCCCTGAACTCGTTTAA AGAGTATTTCAATCTGCGCAATTGCACCTTCATGTATACTTACAATATTACAGAG

[0119] GATGAGATCTTAGAGTGGTTCGGTATTACTCAAACCGCGCAGGGGGTCCACTT GTTTTCGTCACGTTATGTGGATCTTTATGGAGGTAACATGTTCCAGTTTGCTACG TTGCCGGTCTACGATACTATCAAGTATTATTCAATCATTCCGCATTCGATCCGTT CAATCCAGAGTGATCGTAAGGCGTGGGCGGCGTTCTACGTCTATAAACTTCAG CCGCTGACCTTCCTGTTGGACTTTAGTGTGGATGGCTATATTCGCCGTGCGATT GACTGTGGGTTCAATGACTTGAGTCAATTACATTGTAGTTACGAATCTGattacgac atcccaacgaccgaaaacctgtattttcagggcTCAGGCGGTCATCATCATCACCACCATAGTG GTTCCGTACCGACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTG GCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACA ACATACTTATTgcctcgg

[0120] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGAATATTACTAATCTGTGTCCATTCGGCGAGGTTTTTAACGCG ACACGTTTTGCGAGTGTTTACGCATGGAATCGCAAACGTATTAGTAATTGCGTC GCCGACTATTCGGTTTTATATAACTCAGCGTCTTTCAGCACTTTCAAATGTTATG GAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTACGAACGTCTACGCTGACA GCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCGCTCCAGGACAGACCGGA AAGATCGCCGATTACAACTATAAATTGCCTGACGATTTCACGGGATGCGTTATT GCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGCGGTAACTATAACTACCT GTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGAACGTGATATTTCCACA GAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGGGTGGAGGGGTTTAATTG CTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGAATGGCGTGGGTTATCAA CCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGCATGCTCCCGCTACAGTC GattacgacatcccaacgaccgaaaacctgtattttcagggcTCAGGCGGTCATCATCATCACCAC CATAGTGGTTCCGTACCGACTATTGTAATGGTTGATGCATACAAACGCTACAAA GGAAGTGGCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTT AGTTACAACATACTTATTgcctcgg

[0121] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGAGTGACAACGGACCCCAAAATCAGCGCAATGCGCCGCGTAT TACGTTCGGTGGGCCATCAGACTCTACGGGCTCAAATCAAAATGGCGAGCGCT CGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGGTTTACCCAATAACACCGCA TCTTGGTTCACGGCCCTTACACAGCATGGTAAAGAGGACCTGAAGTTCCCCCG CGGACAAGGTGTCCCTATCAATACCAATTCAAGCCCTGACGATCAAATCGGTTA CTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTGACGGGAAGATGAAGGACT TGTCACCGCGCTGGTACTTTTATTACTTAGGGACAGGCCCAGAGGCAGGATTG CCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACGGAGGGAGCCTT GAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAATAACGCGGCAA TCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCTTCTATGCCGAA GGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCACGCTCTCGCAA CTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTCGCCTGCACGCA TGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGTTAGACCGCTTG AACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAACAAGGTCAAACC GTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTCAAAAGCGTAC AGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGCGGTCCTGAGC AGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGGCACAGACTATA AGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTGCTTTCTTCGGA ATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGTTGACCTACAC TGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATCAGGTCATTTTA CTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCAACTGAACCTAAGAAAG ATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAACGCCAGAAAAAG CAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGACTTCTCTAAACA G CTT C AG C AAT CTAT G AGTT C C G CT GATT C AAC C C AAG C C Gattacgacatcccaacga ccgaaaacctgtattttcagggcT C AG G C G GT CAT CAT CAT C AC C AC C ATAGT G GTTC C GT ACCGACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCTAActc gagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACT TATTgcctcgg

[0122] 9. SARS CoV-2 NP 121 -419g gctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatctc gatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaaga aggagatataccATGTTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCC ACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGC AAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAG GCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCA TCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGAC CTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTG CTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAA CAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCC TCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCG TCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCC AAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCA AGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAAC GTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAA AGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCA ACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCT CAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGA TGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGC

[0123] CGattacgacatcccaacgaccgaaaacctgtattttcagggcTCAGGCGGTCATCATCATCACCA CCATAGTGGTTCCGTACCGACTATTGTAATGGTTGATGCATACAAACGCTACAA AGGAAGTGGCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACT TTAGTTACAACATACTTATTgcctcgg

[0124] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTATTCATTTGTCTCTGAGGAGACTGGTACCTTAATCGTCAAT TCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCTGGTCACTTTGGCGATTTT GACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATATCGTCAACGTGTCTCTGGT AAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAACCTTAATAGCTCCCGCGTC CCCGATCTGTTGGTCGattacgacatcccaacgaccgaaaacctgtattttcagggcTCAGGCGGT CATCATCATCACCACCATAGTGGTTCCGTACCGACTATTGTAATGGTTGATGCAT ACAAACGCTACAAAGGAAGTGGCTAActcgagccttaggagatccggctgctaacaaagcccgaa aggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0125] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGGCTGACTCGAATGGCACGATTACCGTCGAGGAATTAAAAAA GTTATTGGAACAATGGAACCTGGTAATCGGCTTCCTGTTTCTTACGTGGATTTGT TTGCTGCAATTTGCCTATGCTAACCGCAACCGTTTCTTATATATTATTAAACTGAT CTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCATGTTTTGTTTTGGCTGCCGT CTATCGCATCAACTGGATTACCGGCGGAATCGCCATTGCTATGGCCTGTTTGGT TGGTCTGATGTGGCTGTCATACTTTATTGCCAGTTTTCGTTTGTTCGCCCGTACA CGCTCTATGTGGAGCTTCAACCCAGAGACAAACATTCTGTTGAATGTTCCTCTG CATGGCACCATTCTGACGCGTCCATTATTAGAGAGTGAATTAGTCATCGGAGCT GTTATTCTGCGCGGACACCTTCGTATCGCCGGTCATCACTTGGGTCGTTGCGA CATCAAGGACTTACCAAAAGAAATTACAGTGGCTACATCACGCACCCTTTCCTAT TATAAATTGGGTGCCTCACAACGCGTTGCCGGAGATTCGGGATTTGCTGCTTAC TCACGTTACCGTATCGGAAATTACAAACTGAATACAGACCACTCTAGCTCATCC GATAACATTGCGCTTTTAGTGCAGGattacgacatcccaacgaccgaaaacctgtattttcagggcT CAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACCGACTATTGTAATGG TTGATGCATACAAACGCTACAAAGGAAGTGGCTAActcgagccttaggagatccggctgcta acaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0126] His-Spy-TEV-POl

[0127] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcCGCGACAAATTAAGCAGCACTAATCAGTTACG CAGTGTCGGATTGAACCTGGAGGGCAACGGCGTCGCCACAGACGTTCCGTCC GCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGGTTGTTAATTA TGAAGCTGGTGAATGGGCCGAAAATTGCTACAACTTAGAGATCAAGAAGCCAGA CGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGCTTTCCTCGCT GCCGTTATGTTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGGTGATTTCGCT TTTCACAAAGAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCAACGGTCATTT ACCGCGGGACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAATTCTGCCCCAA GCTAAGAAGGATTTCTTCTCGTCACATCCTCTTCGTGAGTAActcgagccttaggagatc cggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0128] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcATT C CTTTAG GT GT AAT C C AC AATAG C AC ACTT CAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCTAGTACTAAC CAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGCCACGGATGT CCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTGGAGTGCCGCCTAAAGTGG TCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGTTACAATTTAGAGATTAAAA AACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCCGACGGTATCCGCGGATTT CCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACTGGTCCGTGTGCAGGGGA TTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTATGATCGTCTTGCTTCCACC GTAATTTACCGTGGCACGACGTTTGCTGAGGGGGTGGTAGCGTTCCTGATCCT GCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggagatccggctgctaacaaagcccgaaa ggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0129] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcTTAAGTTCCACTAACCAGCTTCGTAGTGTAGG GTTAAACTTGGAAGGTAACGGAGTAGCTACGGATGTGCCTAGCGCTACGAAGC GTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTACGAAGCAGGC GAATGGGCAGAAAATTGCTATAATCTGGAAATTAAAAAGCCTGACGGCAGCGAA TGTTTACCTGCCGCCCCGGACGGCATCCGTGGATTTCCACGTTGTCGCTACGT GCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTTAActcgagccttaggagatccggctg ctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0130] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcGAAGCCATCGTGAACGCCCAACCCAAATGTAA TCCAAATCTGCATTATTGGACAACACAAGATGAAGGGGCAGCTATCGGCTTAGC CTGGATTCCGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTGAAGGCCTGAT GCACAATCAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCCAACGAAACTA CTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGTACATTCTCAA TCTTAAACCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGAGGTACGTGCC ACATTTTAGGTCCTGACTGCTGTATTGAACCACACGATTGGACTAAGAATATTAC GGACAAGATCGACCAGATTATTCATGATTTTGTTGATAAGACGTTACCGGATCA GGGTGACAATGATAATTGGTGGACGGGCTGGCGTTAActcgagccttaggagatccggctg ctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0131] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcGAAGCCAAACCCAGTGGAAGCGTCGTGGAAC AGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGACACCCCC GCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAATCTTACCA AATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCTCCGGC CGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTTATCCC CTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTCGCAATTT AACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACCGTACCTC ATAATTTAACGACGATCACCAAGCCACTGAAGTACAGCTATATTAATAAATGCAG TCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCAATTGGTTAATGCGAACC AATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGATGGTGATT ACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGGCAAGT GGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGGGCTTCGGCATTACAGTT CAATATGGTACTGACACGAACAGTGTATGCCCTAAGATTGAATTTGCGAATGAC ACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATATTAActcgagccttaggagatcc ggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0132] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcT AC GTT GAT GTC G GTC C AG ACT C G GT AAAAAG TGCTTGCATTGAAGTGGACATTCAACAGACCTTCTTCGATAAAACTTGGCCTCG TCCTATCGATGTTAGCAAGGCGGATGGCATCATCTATCCTCAGGGCCGCACATA TTCGAACATTACCATCACATATCAGGGCTTGTTTCCTTACCAAGGCGACCATGG TGATATGTACGTTTATTCTGCTGGACACGCGACTGGTACTACCCCTCAGAAACT GTTTGTTGCGAACTACTCTCAAGACGTGAAGCAATTTGCGAATGGGTTCGTAGT TCGCATTGGGGCAGCGGCGAACTCAACTGGGACAGTGATTATTTCGCCCAGTA CATCGGCGACGATTCGTAAGATTTATCCAGCCTTCATGTTAGGGTCGTCCGTGG GTAACTTTAGCGACGGGAAGATGGGGCGTTTTTTCAACCACACCCTGGTGTTGT TGCCGGATGGTTGCGGTACCTTACTTCGCGCTTTTTATTGTATTTTAGAGCCCC GCTCTGGTAACCACTGTCCCGCGGGTAACTCATACACATCTTTTGCCACTTACC ACACCCCCGCGACAGACTGCAGCGATGGTAACTATAATCGTAACGCCTCCCTG AACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGCACCTTCATGTATACTTACA ATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTATTACTCAAACCGCGCAGG GGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTTATGGAGGTAACATGTTCCA GTTTGCTACGTTGCCGGTCTACGATACTATCAAGTATTATTCAATCATTCCGCAT TCGATCCGTTCAATCCAGAGTGATCGTAAGGCGTGGGCGGCGTTCTACGTCTA TAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTAGTGTGGATGGCTATATTCG CCGTGCGATTGACTGTGGGTTCAATGACTTGAGTCAATTACATTGTAGTTACGA ATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTA CAACATACTTATTgcctcgg

[0133] 7. SARS CoV-2 RBD 331 -524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcAATATTACTAATCTGTGTCCATTCGGCGAGGTT TTTAACGCGACACGTTTTGCGAGTGTTTACGCATGGAATCGCAAACGTATTAGT AATTGCGTCGCCGACTATTCGGTTTTATATAACTCAGCGTCTTTCAGCACTTTCA AATGTTATGGAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTACGAACGTCTA CGCTGACAGCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCGCTCCAGGACA GACCGGAAAGATCGCCGATTACAACTATAAATTGCCTGACGATTTCACGGGATG CGTTATTGCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGCGGTAACTATAA CTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGAACGTGATATT TCCACAGAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGGGTGGAGGGGTT TAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGAATGGCGTGGGT TATCAACCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGCATGCTCCCGCT ACAGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGT TACAACATACTTATTgcctcgg

[0134] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcAGT G AC AAC G G AC C C C AAAAT C AG C G C AAT G C GCCGCGTATTACGTTCGGTGGGCCATCAGACTCTACGGGCTCAAATCAAAATG GCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGGTTTACCCAAT AACACCGCATCTTGGTTCACGGCCCTTACACAGCATGGTAAAGAGGACCTGAA GTTCCCCCGCGGACAAGGTGTCCCTATCAATACCAATTCAAGCCCTGACGATCA AATCGGTTACTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTGACGGGAAGA TGAAGGACTTGTCACCGCGCTGGTACTTTTATTACTTAGGGACAGGCCCAGAG GCAGGATTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACGGA GGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAATA ACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCTTC TATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCACG CTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTCGC CTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGTTA GACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAACA AGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTC AAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGC GGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGG CACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTG CTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGT TGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATC AGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCAACTGA ACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAAC GCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGAC TTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGCCTAAct cgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATAC TTATTgcctcgg

[0135] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcTTGCCGTATGGAGCGAATAAGGACGGAATCAT CTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACC CGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACT CTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTC CCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTC CCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTG GCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAA GGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTC CAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGC ATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAAC TTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCAC CCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCA GCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCT AATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTT TCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGG CATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCC GACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCA ACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTT AGTTACAACATACTTATTgcctcgg 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcTATTCATTTGTCTCTGAGGAGACTGGTACCTTA ATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCTGGTCACTTT GGCGATTTTGACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATATCGTCAACGT GTCTCTGGTAAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAACCTTAATAGC TCCCGCGTCCCCGATCTGTTGGTCTAActcgagccttaggagatccggctgctaacaaagcccga aaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0136] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGattacgacat cccaacgaccgaaaacctgtattttcagggcGCTGACTCGAATGGCACGATTACCGTCGAGGA ATTAAAAAAGTTATTGGAACAATGGAACCTGGTAATCGGCTTCCTGTTTCTTACG TGGATTTGTTTGCTGCAATTTGCCTATGCTAACCGCAACCGTTTCTTATATATTAT TAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCATGTTTTGTTTTG GCTGCCGTCTATCGCATCAACTGGATTACCGGCGGAATCGCCATTGCTATGGC CTGTTTGGTTGGTCTGATGTGGCTGTCATACTTTATTGCCAGTTTTCGTTTGTTC GCCCGTACACGCTCTATGTGGAGCTTCAACCCAGAGACAAACATTCTGTTGAAT GTTCCTCTGCATGGCACCATTCTGACGCGTCCATTATTAGAGAGTGAATTAGTC ATCGGAGCTGTTATTCTGCGCGGACACCTTCGTATCGCCGGTCATCACTTGGGT CGTTGCGACATCAAGGACTTACCAAAAGAAATTACAGTGGCTACATCACGCACC CTTTCCTATTATAAATTGGGTGCCTCACAACGCGTTGCCGGAGATTCGGGATTT GCTGCTTACTCACGTTACCGTATCGGAAATTACAAACTGAATACAGACCACTCTA GCTCATCCGATAACATTGCGCTTTTAGTGCAGTAActcgagccttaggagatccggctgctaa caaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0137] His-Spy-bdSumo-POl

[0138] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GCGCGACAAATTAAGCAGCACTAATCAGTTACGCAGTGTCGGATTGAACCTGGA GGGCAACGGCGTCGCCACAGACGTTCCGTCCGCCACGAAGCGTTGGGGATTC CGTAGCGGGGTGCCTCCGAAGGTTGTTAATTATGAAGCTGGTGAATGGGCCGA AAATTGCTACAACTTAGAGATCAAGAAGCCAGACGGTTCAGAGTGTCTGCCAGC CGCGCCAGACGGGATTCGCGGCTTTCCTCGCTGCCGTTATGTTCACAAGGTTA GCGGGACGGGGCCGTGTGCCGGTGATTTCGCTTTTCACAAAGAGGGGGCTTTC TTCTTATACGACCGTTTAGCGTCAACGGTCATTTACCGCGGGACAACGTTCGCG GAAGGAGTGGTGGCGTTCTTAATTCTGCCCCAAGCTAAGAAGGATTTCTTCTCG TCACATCCTCTTCGTGAGTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagc tgagCACTTTAGTTACAACATACTTATTgcctcgg

[0139] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GATTCCTTTAGGTGTAATCCACAATAGCACACTTCAGGTAAGTGACGTAGATAAA CTTGTCTGTCGTGATAAGTTGTCTAGTACTAACCAACTGCGTTCTGTCGGGCTT AACCTTGAGGGGAATGGAGTCGCCACGGATGTCCCGTCGGCAACGAAACGCT GGGGATTTCGCTCTGGAGTGCCGCCTAAAGTGGTCAACTATGAAGCAGGCGAG TGGGCGGAGAATTGTTACAATTTAGAGATTAAAAAACCAGACGGGTCTGAGTGC TTACCTGCCGCGCCCGACGGTATCCGCGGATTTCCACGCTGTCGCTATGTGCA CAAAGTTAGTGGTACTGGTCCGTGTGCAGGGGATTTCGCATTTCACAAAGAAGG AGCCTTCTTTCTTTATGATCGTCTTGCTTCCACCGTAATTTACCGTGGCACGACG TTTGCTGAGGGGGTGGTAGCGTTCCTGATCCTGCCGCAAGCAAAAAAGGACTT TTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAA CATACTTATTgcctcgg

[0140] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GTTAAGTTCCACTAACCAGCTTCGTAGTGTAGGGTTAAACTTGGAAGGTAACGG AGTAGCTACGGATGTGCCTAGCGCTACGAAGCGTTGGGGGTTTCGTAGCGGTG TTCCTCCCAAAGTGGTGAACTACGAAGCAGGCGAATGGGCAGAAAATTGCTATA ATCTGGAAATTAAAAAGCCTGACGGCAGCGAATGTTTACCTGCCGCCCCGGAC GGCATCCGTGGATTTCCACGTTGTCGCTACGTGCATAAGGTATCAGGCACCGG CCCTTGTGCGGGTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagC ACTTTAGTTACAACATACTTATTgcctcgg 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GGAAGCCATCGTGAACGCCCAACCCAAATGTAATCCAAATCTGCATTATTGGAC AACACAAGATGAAGGGGCAGCTATCGGCTTAGCCTGGATTCCGTATTTTGGGC CTGCCGCGGAGGGGATTTATATTGAAGGCCTGATGCACAATCAGGACGGTTTG ATCTGCGGCTTGCGCCAGTTAGCCAACGAAACTACTCAAGCCTTGCAGCTGTTC CTGCGCGCTACGACCGAATTGCGTACATTCTCAATCTTAAACCGCAAAGCAATC GACTTCTTACTTCAGCGTTGGGGAGGTACGTGCCACATTTTAGGTCCTGACTGC TGTATTGAACCACACGATTGGACTAAGAATATTACGGACAAGATCGACCAGATT ATTCATGATTTTGTTGATAAGACGTTACCGGATCAGGGTGACAATGATAATTGGT GGACGGGCTGGCGTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgag CACTTTAGTTACAACATACTTATTgcctcgg

[0141] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GGAAGCCAAACCCAGTGGAAGCGTCGTGGAACAGGCAGAAGGTGTGGAGTGC GATTTCTCACCGCTGCTGTCCGGGACACCCCCGCAAGTGTATAACTTCAAACGT TTAGTGTTTACTAACTGTAACTATAATCTTACCAAATTGCTGTCTCTGTTCTCTGT GAATGATTTTACTTGCTCTCAAATTTCTCCGGCCGCGATCGCTTCTAATTGTTAC AGTAGTTTGATTCTTGACTATTTCTCTTATCCCCTTTCCATGAAAAGTGATTTAAG CGTCAGCTCCGCAGGACCGATCTCGCAATTTAACTATAAACAGTCGTTTAGCAA TCCAACGTGTTTAATTCTGGCAACCGTACCTCATAATTTAACGACGATCACCAAG CCACTGAAGTACAGCTATATTAATAAATGCAGTCGTTTGCTGTCGGACGACCGC ACGGAAGTACCCCAATTGGTTAATGCGAACCAATACTCTCCCTGCGTTTCAATT GTACCCTCGACTGTTTGGGAGGATGGTGATTACTACCGCAAACAACTGTCGCC CCTTGAGGGCGGTGGTTGGCTGGTGGCAAGTGGTTCTACGGTTGCAATGACCG AGCAATTGCAAATGGGCTTCGGCATTACAGTTCAATATGGTACTGACACGAACA GTGTATGCCCTAAGATTGAATTTGCGAATGACACTAAAATTGCCTCGCAATTAG GAAACTGTGTCGAATATTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctg agCACTTTAGTTACAACATACTTATTgcctcgg

[0142] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GTACGTTGATGTCGGTCCAGACTCGGTAAAAAGTGCTTGCATTGAAGTGGACAT TCAACAGACCTTCTTCGATAAAACTTGGCCTCGTCCTATCGATGTTAGCAAGGC GGATGGCATCATCTATCCTCAGGGCCGCACATATTCGAACATTACCATCACATA TCAGGGCTTGTTTCCTTACCAAGGCGACCATGGTGATATGTACGTTTATTCTGC TGGACACGCGACTGGTACTACCCCTCAGAAACTGTTTGTTGCGAACTACTCTCA AGACGTGAAGCAATTTGCGAATGGGTTCGTAGTTCGCATTGGGGCAGCGGCGA ACTCAACTGGGACAGTGATTATTTCGCCCAGTACATCGGCGACGATTCGTAAGA TTTATCCAGCCTTCATGTTAGGGTCGTCCGTGGGTAACTTTAGCGACGGGAAGA TGGGGCGTTTTTTCAACCACACCCTGGTGTTGTTGCCGGATGGTTGCGGTACCT TACTTCGCGCTTTTTATTGTATTTTAGAGCCCCGCTCTGGTAACCACTGTCCCGC GGGTAACTCATACACATCTTTTGCCACTTACCACACCCCCGCGACAGACTGCAG CGATGGTAACTATAATCGTAACGCCTCCCTGAACTCGTTTAAAGAGTATTTCAAT CTGCGCAATTGCACCTTCATGTATACTTACAATATTACAGAGGATGAGATCTTAG AGTGGTTCGGTATTACTCAAACCGCGCAGGGGGTCCACTTGTTTTCGTCACGTT ATGTGGATCTTTATGGAGGTAACATGTTCCAGTTTGCTACGTTGCCGGTCTACG ATACTATCAAGTATTATTCAATCATTCCGCATTCGATCCGTTCAATCCAGAGTGA TCGTAAGGCGTGGGCGGCGTTCTACGTCTATAAACTTCAGCCGCTGACCTTCCT GTTGGACTTTAGTGTGGATGGCTATATTCGCCGTGCGATTGACTGTGGGTTCAA TGACTTGAGTCAATTACATTGTAGTTACGAATCTTAActcgagccttaggagatccggctgct aacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0143] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GAATATTACTAATCTGTGTCCATTCGGCGAGGTTTTTAACGCGACACGTTTTGC GAGTGTTTACGCATGGAATCGCAAACGTATTAGTAATTGCGTCGCCGACTATTC GGTTTTATATAACTCAGCGTCTTTCAGCACTTTCAAATGTTATGGAGTTAGTCCA ACGAAGTTGAATGATCTTTGTTTTACGAACGTCTACGCTGACAGCTTCGTTATCC GTGGTGATGAAGTACGTCAAATCGCTCCAGGACAGACCGGAAAGATCGCCGAT TACAACTATAAATTGCCTGACGATTTCACGGGATGCGTTATTGCGTGGAACTCG AACAATCTTGACTCGAAGGTGGGCGGTAACTATAACTACCTGTATCGTCTTTTC CGTAAGTCCAATTTGAAGCCCTTTGAACGTGATATTTCCACAGAAATCTATCAGG CCGGCTCGACGCCGTGCAATGGGGTGGAGGGGTTTAATTGCTATTTTCCACTT CAGTCTTATGGTTTCCAGCCTACGAATGGCGTGGGTTATCAACCCTACCGCGTA GTCGTGTTATCATTCGAGTTGCTGCATGCTCCCGCTACAGTCTAActcgagccttagg agatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctc gg

[0144] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GAGTGACAACGGACCCCAAAATCAGCGCAATGCGCCGCGTATTACGTTCGGTG GGCCATCAGACTCTACGGGCTCAAATCAAAATGGCGAGCGCTCGGGCGCTCGT AGCAAGCAACGCCGTCCTCAAGGTTTACCCAATAACACCGCATCTTGGTTCACG GCCCTTACACAGCATGGTAAAGAGGACCTGAAGTTCCCCCGCGGACAAGGTGT CCCTATCAATACCAATTCAAGCCCTGACGATCAAATCGGTTACTACCGTCGTGC TACTCGTCGTATCCGTGGTGGTGACGGGAAGATGAAGGACTTGTCACCGCGCT GGTACTTTTATTACTTAGGGACAGGCCCAGAGGCAGGATTGCCGTATGGAGCG AATAAGGACGGAATCATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAA AGACCACATCGGCACCCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATT GCCACAGGGCACGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTG GAAGCCAAGCCTCCTCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACT CAACCCCTGGCTCTTCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGT GGCGATGCAGCCCTGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAG TAAGATGTCAGGAAAAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTC AGCAGCGGAAGCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCT ACAATGTTACACAGGCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAAC TTTGGAGACCAAGAACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAA ATCGCACAGTTTGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGA ATGGAAGTCACTCCCAGCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCT TGATGACAAGGACCCTAATTTTAAAGATCAGGTCATTTTACTTAATAAACATATC GACGCGTACAAAACTTTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAG GCAGACGAAACCCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCAC TCTGCTGCCGGCCGCCGACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTAT GAGTTCCGCTGATTCAACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagccc gaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0145] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GTTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACGGAGGGA GCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAATAACGC GGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCTTCTATG CCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCACGCTCT CGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTCGCCTGC ACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGTTAGACC GCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAACAAGGT CAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTCAAAA GCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGCGGTC CTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGGCACA GACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTGCTTTC TTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGTTGAC CTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATCAGGT CATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCAACTGAACCT AAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAACGCCA GAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGACTTCT CTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGCCTAActcgag ccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTAT Tgcctcgg

[0146] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GTATTCATTTGTCTCTGAGGAGACTGGTACCTTAATCGTCAATTCAGTGCTTTTA TTCTTAGCTTTTGTAGTGTTCTTGCTGGTCACTTTGGCGATTTTGACCGCGTTGC GTTTGTGTGCTTACTGTTGTAATATCGTCAACGTGTCTCTGGTAAAACCATCTTT CTATGTCTATTCCCGCGTAAAAAACCTTAATAGCTCCCGCGTCCCCGATCTGTT GGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTA CAACATACTTATTgcctcgg

[0147] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcatatcaacctg aaagtgaaaggtcaagacggcaacgaagtctttttccgcatcaaacgttctacccagctgaaaaagctgatgaacg catactgtgaccgtcagtctgtagacatgaccgcaattgctttcctgtttgatggtcgtcgcctgcgtgcggaacagacc ccggatgaactggagatggaagatggcgacgaaatcgacgcaatgcttcatcagactggtggcGGCGGTGG GGCTGACTCGAATGGCACGATTACCGTCGAGGAATTAAAAAAGTTATTGGAACA ATGGAACCTGGTAATCGGCTTCCTGTTTCTTACGTGGATTTGTTTGCTGCAATTT GCCTATGCTAACCGCAACCGTTTCTTATATATTATTAAACTGATCTTCTTGTGGC TGCTTTGGCCGGTAACATTAGCATGTTTTGTTTTGGCTGCCGTCTATCGCATCAA CTGGATTACCGGCGGAATCGCCATTGCTATGGCCTGTTTGGTTGGTCTGATGTG GCTGTCATACTTTATTGCCAGTTTTCGTTTGTTCGCCCGTACACGCTCTATGTGG AGCTTCAACCCAGAGACAAACATTCTGTTGAATGTTCCTCTGCATGGCACCATT CTGACGCGTCCATTATTAGAGAGTGAATTAGTCATCGGAGCTGTTATTCTGCGC GGACACCTTCGTATCGCCGGTCATCACTTGGGTCGTTGCGACATCAAGGACTTA CCAAAAGAAATTACAGTGGCTACATCACGCACCCTTTCCTATTATAAATTGGGTG CCTCACAACGCGTTGCCGGAGATTCGGGATTTGCTGCTTACTCACGTTACCGTA TCGGAAATTACAAACTGAATACAGACCACTCTAGCTCATCCGATAACATTGCGC TTTTAGTGCAGTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACT TTAGTTACAACATACTTATTgcctcgg

[0148] His-Spy-ScSumo-POl

[0149] 1. EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGCGCGACAAATTAA GCAGCACTAATCAGTTACGCAGTGTCGGATTGAACCTGGAGGGCAACGGCGTC GCCACAGACGTTCCGTCCGCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGC CTCCGAAGGTTGTTAATTATGAAGCTGGTGAATGGGCCGAAAATTGCTACAACT TAGAGATCAAGAAGCCAGACGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGG GATTCGCGGCTTTCCTCGCTGCCGTTATGTTCACAAGGTTAGCGGGACGGGGC CGTGTGCCGGTGATTTCGCTTTTCACAAAGAGGGGGCTTTCTTCTTATACGACC GTTTAGCGTCAACGGTCATTTACCGCGGGACAACGTTCGCGGAAGGAGTGGTG GCGTTCTTAATTCTGCCCCAAGCTAAGAAGGATTTCTTCTCGTCACATCCTCTTC GTGAGTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTT ACAACATACTTATT gcctcgg

[0150] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGATTCCTTTAGGTGT AATCCACAATAGCACACTTCAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGA TAAGTTGTCTAGTACTAACCAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAA TGGAGTCGCCACGGATGTCCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTG GAGTGCCGCCTAAAGTGGTCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGT TACAATTTAGAGATTAAAAAACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCC GACGGTATCCGCGGATTTCCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACT GGTCCGTGTGCAGGGGATTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTAT GATCGTCTTGCTTCCACCGTAATTTACCGTGGCACGACGTTTGCTGAGGGGGT GGTAGCGTTCCTGATCCTGCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggaga tccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0151] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGTTAAGTTCCACTAA CCAGCTTCGTAGTGTAGGGTTAAACTTGGAAGGTAACGGAGTAGCTACGGATG TGCCTAGCGCTACGAAGCGTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTG GTGAACTACGAAGCAGGCGAATGGGCAGAAAATTGCTATAATCTGGAAATTAAA AAGCCTGACGGCAGCGAATGTTTACCTGCCGCCCCGGACGGCATCCGTGGATT TCCACGTTGTCGCTACGTGCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTT AActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACA TACTTATTgcctcgg

[0152] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGGAAGCCATCGTGA ACGCCCAACCCAAATGTAATCCAAATCTGCATTATTGGACAACACAAGATGAAG GGGCAGCTATCGGCTTAGCCTGGATTCCGTATTTTGGGCCTGCCGCGGAGGG GATTTATATTGAAGGCCTGATGCACAATCAGGACGGTTTGATCTGCGGCTTGCG CCAGTTAGCCAACGAAACTACTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGA CCGAATTGCGTACATTCTCAATCTTAAACCGCAAAGCAATCGACTTCTTACTTCA GCGTTGGGGAGGTACGTGCCACATTTTAGGTCCTGACTGCTGTATTGAACCACA CGATTGGACTAAGAATATTACGGACAAGATCGACCAGATTATTCATGATTTTGTT GATAAGACGTTACCGGATCAGGGTGACAATGATAATTGGTGGACGGGCTGGCG TTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAA

[0153] CATACTTATTgcctcgg

[0154] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGGAAGCCAAACCCA GTGGAAGCGTCGTGGAACAGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTG CTGTCCGGGACACCCCCGCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAAC TGTAACTATAATCTTACCAAATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTG CTCTCAAATTTCTCCGGCCGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTT GACTATTTCTCTTATCCCCTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAG GACCGATCTCGCAATTTAACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAAT TCTGGCAACCGTACCTCATAATTTAACGACGATCACCAAGCCACTGAAGTACAG CTATATTAATAAATGCAGTCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCA ATTGGTTAATGCGAACCAATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTT TGGGAGGATGGTGATTACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGG TTGGCTGGTGGCAAGTGGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGG GCTTCGGCATTACAGTTCAATATGGTACTGACACGAACAGTGTATGCCCTAAGA TTGAATTTGCGAATGACACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATA TTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAA CATACTTATTgcctcgg

[0155] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGTACGTTGATGTCG GTCCAGACTCGGTAAAAAGTGCTTGCATTGAAGTGGACATTCAACAGACCTTCT TCGATAAAACTTGGCCTCGTCCTATCGATGTTAGCAAGGCGGATGGCATCATCT ATCCTCAGGGCCGCACATATTCGAACATTACCATCACATATCAGGGCTTGTTTC CTTACCAAGGCGACCATGGTGATATGTACGTTTATTCTGCTGGACACGCGACTG GTACTACCCCTCAGAAACTGTTTGTTGCGAACTACTCTCAAGACGTGAAGCAAT TTGCGAATGGGTTCGTAGTTCGCATTGGGGCAGCGGCGAACTCAACTGGGACA GTGATTATTTCGCCCAGTACATCGGCGACGATTCGTAAGATTTATCCAGCCTTC ATGTTAGGGTCGTCCGTGGGTAACTTTAGCGACGGGAAGATGGGGCGTTTTTT CAACCACACCCTGGTGTTGTTGCCGGATGGTTGCGGTACCTTACTTCGCGCTTT TTATTGTATTTTAGAGCCCCGCTCTGGTAACCACTGTCCCGCGGGTAACTCATA CACATCTTTTGCCACTTACCACACCCCCGCGACAGACTGCAGCGATGGTAACTA TAATCGTAACGCCTCCCTGAACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGC ACCTTCATGTATACTTACAATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTA TTACTCAAACCGCGCAGGGGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTT ATGGAGGTAACATGTTCCAGTTTGCTACGTTGCCGGTCTACGATACTATCAAGT ATTATTCAATCATTCCGCATTCGATCCGTTCAATCCAGAGTGATCGTAAGGCGT GGGCGGCGTTCTACGTCTATAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTA GTGTGGATGGCTATATTCGCCGTGCGATTGACTGTGGGTTCAATGACTTGAGTC AATTACATTGTAGTTACGAATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaa ggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0156] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGAATATTACTAATCT GTGTCCATTCGGCGAGGTTTTTAACGCGACACGTTTTGCGAGTGTTTACGCATG GAATCGCAAACGTATTAGTAATTGCGTCGCCGACTATTCGGTTTTATATAACTCA GCGTCTTTCAGCACTTTCAAATGTTATGGAGTTAGTCCAACGAAGTTGAATGATC TTTGTTTTACGAACGTCTACGCTGACAGCTTCGTTATCCGTGGTGATGAAGTAC GTCAAATCGCTCCAGGACAGACCGGAAAGATCGCCGATTACAACTATAAATTGC CTGACGATTTCACGGGATGCGTTATTGCGTGGAACTCGAACAATCTTGACTCGA AGGTGGGCGGTAACTATAACTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAA GCCCTTTGAACGTGATATTTCCACAGAAATCTATCAGGCCGGCTCGACGCCGTG CAATGGGGTGGAGGGGTTTAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCA GCCTACGAATGGCGTGGGTTATCAACCCTACCGCGTAGTCGTGTTATCATTCGA GTTGCTGCATGCTCCCGCTACAGTCTAActcgagccttaggagatccggctgctaacaaagccc gaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0157] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGAGTGACAACGGAC CCCAAAATCAGCGCAATGCGCCGCGTATTACGTTCGGTGGGCCATCAGACTCT ACGGGCTCAAATCAAAATGGCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCC GTCCTCAAGGTTTACCCAATAACACCGCATCTTGGTTCACGGCCCTTACACAGC ATGGTAAAGAGGACCTGAAGTTCCCCCGCGGACAAGGTGTCCCTATCAATACC AATTCAAGCCCTGACGATCAAATCGGTTACTACCGTCGTGCTACTCGTCGTATC CGTGGTGGTGACGGGAAGATGAAGGACTTGTCACCGCGCTGGTACTTTTATTA CTTAGGGACAGGCCCAGAGGCAGGATTGCCGTATGGAGCGAATAAGGACGGA ATCATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGG CACCCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCA CGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCC TCCTCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGC TCTTCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAG CCCTGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAG GAAAAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAA GCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACA CAGGCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCA AGAACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTT TGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCAC TCCCAGCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGG ACCCTAATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAA

[0158] AACTTTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAAC CCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGG CCGCCGACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTG ATTCAACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagC ACTTTAGTTACAACATACTTATTgcctcgg

[0159] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGTTGCCGTATGGAG CGAATAAGGACGGAATCATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCC AAAGACCACATCGGCACCCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAA TTGCCACAGGGCACGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGG TGGAAGCCAAGCCTCCTCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTA ACTCAACCCCTGGCTCTTCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAAC GGTGGCGATGCAGCCCTGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGA AAGTAAGATGTCAGGAAAAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAA GTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAG CCTACAATGTTACACAGGCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGT AACTTTGGAGACCAAGAACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCC CAAATCGCACAGTTTGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATC GGAATGGAAGTCACTCCCAGCGGAACGTGGTTGACCTACACTGGTGCGATCAA GCTTGATGACAAGGACCCTAATTTTAAAGATCAGGTCATTTTACTTAATAAACAT ATCGACGCGTACAAAACTTTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAA AAGGCAGACGAAACCCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGT CACTCTGCTGCCGGCCGCCGACCTGGATGACTTCTCTAAACAGCTTCAGCAAT CTATGAGTTCCGCTGATTCAACCCAAGCCTAActcgagccttaggagatccggctgctaacaa agcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0160] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGTATTCATTTGTCTC TGAGGAGACTGGTACCTTAATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTA GTGTTCTTGCTGGTCACTTTGGCGATTTTGACCGCGTTGCGTTTGTGTGCTTAC TGTTGTAATATCGTCAACGTGTCTCTGGTAAAACCATCTTTCTATGTCTATTCCC GCGTAAAAAACCTTAATAGCTCCCGCGTCCCCGATCTGTTGGTCTAActcgagcctta ggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcc tcgg

[0161] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCgactcagaagt caatcaagaagctaagccagaggtcaagccagaagtcaagcctgagactcacatcaatttaaaggtgtccgatgg atcttcagaaatcttctttaagatcaaaaagaccactcctttaagaaggctgatggaagcgttcgctaaaagacagggt aaggaaatggactccttaagattcttgtacgacggtattagaattcaagctgatcagacccctgaagatttggacatgg aggataacgatattattgaggctcacagagaacagattggtggtGGCGGTGGGGCTGACTCGAATG GCACGATTACCGTCGAGGAATTAAAAAAGTTATTGGAACAATGGAACCTGGTAA TCGGCTTCCTGTTTCTTACGTGGATTTGTTTGCTGCAATTTGCCTATGCTAACCG CAACCGTTTCTTATATATTATTAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTA ACATTAGCATGTTTTGTTTTGGCTGCCGTCTATCGCATCAACTGGATTACCGGC GGAATCGCCATTGCTATGGCCTGTTTGGTTGGTCTGATGTGGCTGTCATACTTT ATTGCCAGTTTTCGTTTGTTCGCCCGTACACGCTCTATGTGGAGCTTCAACCCA GAGACAAACATTCTGTTGAATGTTCCTCTGCATGGCACCATTCTGACGCGTCCA TTATTAGAGAGTGAATTAGTCATCGGAGCTGTTATTCTGCGCGGACACCTTCGT ATCGCCGGTCATCACTTGGGTCGTTGCGACATCAAGGACTTACCAAAAGAAATT ACAGTGGCTACATCACGCACCCTTTCCTATTATAAATTGGGTGCCTCACAACGC GTTGCCGGAGATTCGGGATTTGCTGCTTACTCACGTTACCGTATCGGAAATTAC AAACTGAATACAGACCACTCTAGCTCATCCGATAACATTGCGCTTTTAGTGCAGT AActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACA TACTTATTgcctcgg

[0162] His-Spy-PpiB-TEV-POl

[0163] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0164] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT

[0165] GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA

[0166] CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcCGCGACAAATTAAGCAGCACTAATCA GTTACGCAGTGTCGGATTGAACCTGGAGGGCAACGGCGTCGCCACAGACGTTC CGTCCGCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGGTTGT

[0167] TAATTATGAAGCTGGTGAATGGGCCGAAAATTGCTACAACTTAGAGATCAAGAA GCCAGACGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGCTTT CCTCGCTGCCGTTATGTTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGGTG ATTTCGCTTTTCACAAAGAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCAAC

[0168] GGTCATTTACCGCGGGACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAATTC

[0169] TGCCCCAAGCTAAGAAGGATTTCTTCTCGTCACATCCTCTTCGTGAGTAActcgag ccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTAT Tgcctcgg

[0170] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0171] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC

[0172] ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC

[0173] ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcATTCCTTTAGGTGTAATCCACAATAG

[0174] CACACTTCAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCTAGT

[0175] ACTAACCAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGCCAC

[0176] GGATGTCCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTGGAGTGCCGCCTA

[0177] AAGTGGTCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGTTACAATTTAGAG

[0178] ATTAAAAAACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCCGACGGTATCCG

[0179] CGGATTTCCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACTGGTCCGTGTGC

[0180] AGGGGATTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTATGATCGTCTTGCT

[0181] TCCACCGTAATTTACCGTGGCACGACGTTTGCTGAGGGGGTGGTAGCGTTCCT

[0182] GATCCTGCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggagatccggctgctaacaaag cccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0183] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0184] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0185] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA

[0186] AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT

[0187] TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC

[0188] ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT

[0189] GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG

[0190] CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG

[0191] GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC

[0192] ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA

[0193] CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcTTAAGTTCCACTAACCAGCTTCGTAG

[0194] TGTAGGGTTAAACTTGGAAGGTAACGGAGTAGCTACGGATGTGCCTAGCGCTA

[0195] CGAAGCGTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTACGAA

[0196] GCAGGCGAATGGGCAGAAAATTGCTATAATCTGGAAATTAAAAAGCCTGACGGC

[0197] AGCGAATGTTTACCTGCCGCCCCGGACGGCATCCGTGGATTTCCACGTTGTCG

[0198] CTACGTGCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTTAActcgagccttaggag atccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0199] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0200] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0201] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA

[0202] AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT

[0203] TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC

[0204] ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT

[0205] GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG

[0206] CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcGAAGCCATCGTGAACGCCCAACCCA AATGTAATCCAAATCTGCATTATTGGACAACACAAGATGAAGGGGCAGCTATCG GCTTAGCCTGGATTCCGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTGAAG GCCTGATGCACAATCAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCCAAC GAAACTACTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGTACA TTCTCAATCTTAAACCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGAGGT ACGTGCCACATTTTAGGTCCTGACTGCTGTATTGAACCACACGATTGGACTAAG AATATTACGGACAAGATCGACCAGATTATTCATGATTTTGTTGATAAGACGTTAC CGGATCAGGGTGACAATGATAATTGGTGGACGGGCTGGCGTTAActcgagccttagg agatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctc gg

[0207] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcGAAGCCAAACCCAGTGGAAGCGTCG TGGAACAGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGACA CCCCCGCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAATC TTACCAAATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCT CCGGCCGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTT ATCCCCTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTCGC AATTTAACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACCGT ACCTCATAATTTAACGACGATCACCAAGCCACTGAAGTACAGCTATATTAATAAA TGCAGTCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCAATTGGTTAATGC GAACCAATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGATGG TGATTACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGG CAAGTGGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGGGCTTCGGCATTA CAGTTCAATATGGTACTGACACGAACAGTGTATGCCCTAAGATTGAATTTGCGA ATGACACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATATTAActcgagccttag gagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcct egg 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcTACGTTGATGTCGGTCCAGACTCGG TAAAAAGTGCTTGCATTGAAGTGGACATTCAACAGACCTTCTTCGATAAAACTTG GCCTCGTCCTATCGATGTTAGCAAGGCGGATGGCATCATCTATCCTCAGGGCC GCACATATTCGAACATTACCATCACATATCAGGGCTTGTTTCCTTACCAAGGCG ACCATGGTGATATGTACGTTTATTCTGCTGGACACGCGACTGGTACTACCCCTC AGAAACTGTTTGTTGCGAACTACTCTCAAGACGTGAAGCAATTTGCGAATGGGT TCGTAGTTCGCATTGGGGCAGCGGCGAACTCAACTGGGACAGTGATTATTTCG CCCAGTACATCGGCGACGATTCGTAAGATTTATCCAGCCTTCATGTTAGGGTCG TCCGTGGGTAACTTTAGCGACGGGAAGATGGGGCGTTTTTTCAACCACACCCT GGTGTTGTTGCCGGATGGTTGCGGTACCTTACTTCGCGCTTTTTATTGTATTTTA GAGCCCCGCTCTGGTAACCACTGTCCCGCGGGTAACTCATACACATCTTTTGCC ACTTACCACACCCCCGCGACAGACTGCAGCGATGGTAACTATAATCGTAACGC CTCCCTGAACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGCACCTTCATGTAT ACTTACAATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTATTACTCAAACCG CGCAGGGGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTTATGGAGGTAACA TGTTCCAGTTTGCTACGTTGCCGGTCTACGATACTATCAAGTATTATTCAATCAT TCCGCATTCGATCCGTTCAATCCAGAGTGATCGTAAGGCGTGGGCGGCGTTCT ACGTCTATAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTAGTGTGGATGGCT ATATTCGCCGTGCGATTGACTGTGGGTTCAATGACTTGAGTCAATTACATTGTA GTTACGAATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACT TTAGTTACAACATACTTATTgcctcgg

[0208] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG

[0209] GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC

[0210] ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA

[0211] CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcAATATTACTAATCTGTGTCCATTCGG

[0212] CGAGGTTTTTAACGCGACACGTTTTGCGAGTGTTTACGCATGGAATCGCAAACG

[0213] TATTAGTAATTGCGTCGCCGACTATTCGGTTTTATATAACTCAGCGTCTTTCAGC

[0214] ACTTTCAAATGTTATGGAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTACGA

[0215] ACGTCTACGCTGACAGCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCGCTC

[0216] CAGGACAGACCGGAAAGATCGCCGATTACAACTATAAATTGCCTGACGATTTCA

[0217] CGGGATGCGTTATTGCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGCGGT

[0218] AACTATAACTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGAAC

[0219] GTGATATTTCCACAGAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGGGTG

[0220] GAGGGGTTTAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGAATG

[0221] GCGTGGGTTATCAACCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGCATG

[0222] CTCCCGCTACAGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagC ACTTTAGTTACAACATACTTATTgcctcgg

[0223] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0224] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0225] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA

[0226] AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT

[0227] TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC

[0228] ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT

[0229] GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG

[0230] CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG

[0231] GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC

[0232] ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA

[0233] CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcAGTGACAACGGACCCCAAAATCAGC

[0234] GCAATGCGCCGCGTATTACGTTCGGTGGGCCATCAGACTCTACGGGCTCAAAT

[0235] CAAAATGGCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGGTTT

[0236] ACCCAATAACACCGCATCTTGGTTCACGGCCCTTACACAGCATGGTAAAGAGGA

[0237] CCTGAAGTTCCCCCGCGGACAAGGTGTCCCTATCAATACCAATTCAAGCCCTGA

[0238] CGATCAAATCGGTTACTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTGACG

[0239] GGAAGATGAAGGACTTGTCACCGCGCTGGTACTTTTATTACTTAGGGACAGGCC

[0240] CAGAGGCAGGATTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCC

[0241] ACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGC

[0242] AAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAG

[0243] GCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCA TCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGAC CTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTG CTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAA CAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCC

[0244] TCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCG

[0245] TCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCC

[0246] AAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCA

[0247] AGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAAC GTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAA AGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCA ACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCT

[0248] CAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGA TGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGC CTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAA CATACTTATTgcctcgg

[0249] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0250] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA

[0251] AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG

[0252] CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcTTGCCGTATGGAGCGAATAAGGACG

[0253] GAATCATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATC

[0254] GGCACCCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGG CACGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAG CCTCCTCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTG GCTCTTCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGC

[0255] AGCCCTGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTC

[0256] AGGAAAAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGG AAGCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTA CACAGGCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGAC CAAGAACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAG

[0257] TTTGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTC

[0258] ACTCCCAGCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAA GGACCCTAATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTAC AAAACTTTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAA ACCCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCC GGCCGCCGACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGC

[0259] TGATTCAACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctga gCACTTTAGTTACAACATACTTATTgcctcgg

[0260] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0261] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0262] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA

[0263] AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT

[0264] TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC

[0265] ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG

[0266] CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG

[0267] GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC

[0268] ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA

[0269] CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcTATTCATTTGTCTCTGAGGAGACTGG

[0270] TACCTTAATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCTGG

[0271] TCACTTTGGCGATTTTGACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATATCGT CAACGTGTCTCTGGTAAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAACCTT AATAGCTCCCGCGTCCCCGATCTGTTGGTCTAActcgagccttaggagatccggctgctaaca aagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0272] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0273] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTTACTTT

[0274] CCACACCAATCACGGCGATATTGTCATCAAAACTTTTGACGATAAAGCACCTGA

[0275] AACAGTTAAAAACTTCCTGGACTACTGCCGCGAAGGTTTTTACAACAACACCATT

[0276] TTCCACCGTGTTATCAACGGCTTTATGATTCAGGGCGGCGGTTTTGAACCGGGC

[0277] ATGAAACAAAAAGCCACCAAAGAACCGATCAAAAACGAAGCCAACAACGGCCT GAAAAATACCCGTGGTACGCTGGCAATGGCACGTACTCAGGCTCCGCACTCTG

[0278] CAACTGCACAGTTCTTCATCAACGTGGTTGATAACGACTTCCTGAACTTCTCTG

[0279] GCGAAAGCCTGCAAGGTTGGGGCTACTGCGTGTTTGCTGAAGTGGTTGACGGC

[0280] ATGGACGTGGTAGACAAAATCAAAGGTGTTGCAACCGGTCGTAGCGGTATGCA

[0281] CCAGGACGTGCCAAAAGAAGACGTTATCATTGAAAGCGTGACCGTTAGCGAGG attacgacatcccaacgaccgaaaacctgtattttcagggcGCTGACTCGAATGGCACGATTACCG

[0282] TCGAGGAATTAAAAAAGTTATTGGAACAATGGAACCTGGTAATCGGCTTCCTGT

[0283] TTCTTACGTGGATTTGTTTGCTGCAATTTGCCTATGCTAACCGCAACCGTTTCTT ATATATTATTAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCATGT TTTGTTTTGGCTGCCGTCTATCGCATCAACTGGATTACCGGCGGAATCGCCATT GCTATGGCCTGTTTGGTTGGTCTGATGTGGCTGTCATACTTTATTGCCAGTTTTC GTTTGTTCGCCCGTACACGCTCTATGTGGAGCTTCAACCCAGAGACAAACATTC TGTTGAATGTTCCTCTGCATGGCACCATTCTGACGCGTCCATTATTAGAGAGTG AATTAGTCATCGGAGCTGTTATTCTGCGCGGACACCTTCGTATCGCCGGTCATC ACTTGGGTCGTTGCGACATCAAGGACTTACCAAAAGAAATTACAGTGGCTACAT CACGCACCCTTTCCTATTATAAATTGGGTGCCTCACAACGCGTTGCCGGAGATT CGGGATTTGCTGCTTACTCACGTTACCGTATCGGAAATTACAAACTGAATACAG ACCACTCTAGCTCATCCGATAACATTGCGCTTTTAGTGCAGTAActcgagccttaggag atccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0284] His-Spy-Trx-TEV-POl

[0285] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcCGCGACAAATTAAGCAGCACTAATCAGTTA CGCAGTGTCGGATTGAACCTGGAGGGCAACGGCGTCGCCACAGACGTTCCGT CCGCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGGTTGTTAAT TATGAAGCTGGTGAATGGGCCGAAAATTGCTACAACTTAGAGATCAAGAAGCCA GACGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGCTTTCCTC GCTGCCGTTATGTTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGGTGATTTC GCTTTTCACAAAGAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCAACGGTC ATTTACCGCGGGACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAATTCTGCC CCAAGCTAAGAAGGATTTCTTCTCGTCACATCCTCTTCGTGAGTAActcgagccttagg agatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctc gg

[0286] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcATTCCTTTAGGTGTAATCCACAATAGCACAC TTCAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCTAGTACTAA CCAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGCCACGGATG TCCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTGGAGTGCCGCCTAAAGTG GTCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGTTACAATTTAGAGATTAAA AAACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCCGACGGTATCCGCGGATT TCCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACTGGTCCGTGTGCAGGGG ATTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTATGATCGTCTTGCTTCCAC CGTAATTTACCGTGGCACGACGTTTGCTGAGGGGGTGGTAGCGTTCCTGATCC TGCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggagatccggctgctaacaaagcccgaa aggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0287] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcTTAAGTTCCACTAACCAGCTTCGTAGTGTAG

[0288] GGTTAAACTTGGAAGGTAACGGAGTAGCTACGGATGTGCCTAGCGCTACGAAG CGTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTACGAAGCAGG CGAATGGGCAGAAAATTGCTATAATCTGGAAATTAAAAAGCCTGACGGCAGCGA ATGTTTACCTGCCGCCCCGGACGGCATCCGTGGATTTCCACGTTGTCGCTACG TGCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTTAActcgagccttaggagatccggc tgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0289] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcGAAGCCATCGTGAACGCCCAACCCAAATGT AATCCAAATCTGCATTATTGGACAACACAAGATGAAGGGGCAGCTATCGGCTTA GCCTGGATTCCGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTGAAGGCCT

[0290] GATGCACAATCAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCCAACGAAA

[0291] CTACTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGTACATTCT

[0292] CAATCTTAAACCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGAGGTACGT

[0293] GCCACATTTTAGGTCCTGACTGCTGTATTGAACCACACGATTGGACTAAGAATA TTACGGACAAGATCGACCAGATTATTCATGATTTTGTTGATAAGACGTTACCGGA TCAGGGTGACAATGATAATTGGTGGACGGGCTGGCGTTAActcgagccttaggagatcc ggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0294] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA

[0295] AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG

[0296] GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG

[0297] CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA

[0298] AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA

[0299] TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT

[0300] GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcGAAGCCAAACCCAGTGGAAGCGTCGTGGA ACAGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGACACCCC CGCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAATCTTACC

[0301] AAATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCTCCGG

[0302] CCGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTTATCC

[0303] CCTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTCGCAATT

[0304] TAACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACCGTACCT

[0305] CATAATTTAACGACGATCACCAAGCCACTGAAGTACAGCTATATTAATAAATGCA

[0306] GTCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCAATTGGTTAATGCGAAC

[0307] CAATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGATGGTGAT

[0308] TACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGGCAAG

[0309] TGGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGGGCTTCGGCATTACAGT

[0310] TCAATATGGTACTGACACGAACAGTGTATGCCCTAAGATTGAATTTGCGAATGA CACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATATTAActcgagccttaggagat ccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0311] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG

[0312] GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG

[0313] CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcTACGTTGATGTCGGTCCAGACTCGGTAAAA AGTGCTTGCATTGAAGTGGACATTCAACAGACCTTCTTCGATAAAACTTGGCCT

[0314] CGTCCTATCGATGTTAGCAAGGCGGATGGCATCATCTATCCTCAGGGCCGCAC

[0315] ATATTCGAACATTACCATCACATATCAGGGCTTGTTTCCTTACCAAGGCGACCAT

[0316] GGTGATATGTACGTTTATTCTGCTGGACACGCGACTGGTACTACCCCTCAGAAA

[0317] CTGTTTGTTGCGAACTACTCTCAAGACGTGAAGCAATTTGCGAATGGGTTCGTA

[0318] GTTCGCATTGGGGCAGCGGCGAACTCAACTGGGACAGTGATTATTTCGCCCAG TACATCGGCGACGATTCGTAAGATTTATCCAGCCTTCATGTTAGGGTCGTCCGT

[0319] GGGTAACTTTAGCGACGGGAAGATGGGGCGTTTTTTCAACCACACCCTGGTGT

[0320] TGTTGCCGGATGGTTGCGGTACCTTACTTCGCGCTTTTTATTGTATTTTAGAGCC

[0321] CCGCTCTGGTAACCACTGTCCCGCGGGTAACTCATACACATCTTTTGCCACTTA

[0322] CCACACCCCCGCGACAGACTGCAGCGATGGTAACTATAATCGTAACGCCTCCC

[0323] TGAACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGCACCTTCATGTATACTTA CAATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTATTACTCAAACCGCGCA

[0324] GGGGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTTATGGAGGTAACATGTT CCAGTTTGCTACGTTGCCGGTCTACGATACTATCAAGTATTATTCAATCATTCCG CATTCGATCCGTTCAATCCAGAGTGATCGTAAGGCGTGGGCGGCGTTCTACGT

[0325] CTATAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTAGTGTGGATGGCTATATT CGCCGTGCGATTGACTGTGGGTTCAATGACTTGAGTCAATTACATTGTAGTTAC

[0326] GAATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGT TACAACATACTTATTgcctcgg

[0327] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA

[0328] AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG

[0329] CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA

[0330] AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcAATATTACTAATCTGTGTCCATTCGGCGAGG

[0331] TTTTTAACGCGACACGTTTTGCGAGTGTTTACGCATGGAATCGCAAACGTATTA

[0332] GTAATTGCGTCGCCGACTATTCGGTTTTATATAACTCAGCGTCTTTCAGCACTTT CAAATGTTATGGAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTACGAACGTC TACGCTGACAGCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCGCTCCAGGA CAGACCGGAAAGATCGCCGATTACAACTATAAATTGCCTGACGATTTCACGGGA

[0333] TGCGTTATTGCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGCGGTAACTAT

[0334] AACTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGAACGTGATA TTTCCACAGAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGGGTGGAGGGG TTTAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGAATGGCGTGG GTTATCAACCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGCATGCTCCCG CTACAGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTA GTTACAACATACTTATTgcctcgg

[0335] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcAGT G AC AAC G G AC C C C AAAAT C AG C G C AAT GCGCCGCGTATTACGTTCGGTGGGCCATCAGACTCTACGGGCTCAAATCAAAA TGGCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGGTTTACCCA ATAACACCGCATCTTGGTTCACGGCCCTTACACAGCATGGTAAAGAGGACCTGA AGTTCCCCCGCGGACAAGGTGTCCCTATCAATACCAATTCAAGCCCTGACGATC AAATCGGTTACTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTGACGGGAAG ATGAAGGACTTGTCACCGCGCTGGTACTTTTATTACTTAGGGACAGGCCCAGAG GCAGGATTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACGGA GGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAATA ACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCTTC TATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCACG CTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTCGC CTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGTTA GACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAACA AGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTC AAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGC GGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGG CACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTG CTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGT TGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATC AGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCAACTGA ACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAAC GCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGAC TTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGCCTAAct cgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATAC TTATTgcctcgg

[0336] 9. SARS CoV-2 NP 121 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcTTGCCGTATGGAGCGAATAAGGACGGAATC ATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCAC CCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGA CTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCC TCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCT TCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCC TGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAA AAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCG TCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAG GCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGA ACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGC ACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCC CAGCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACC CTAATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACT TTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAG GCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGC CGACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTC AACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTT TAGTTACAACATACTTATTgcctcgg

[0337] 10. SARS CoV-2 E 1 -75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcT ATT C ATTT GTCTCT GAG GAG ACT G GTAC CT TAATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCTGGTCACT TTGGCGATTTTGACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATATCGTCAAC GTGTCTCTGGTAAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAACCTTAATA GCTCCCGCGTCCCCGATCTGTTGGTCTAActcgagccttaggagatccggctgctaacaaagcc cgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg 1 1 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCAGCGATAA AATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCG CCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCGTTGCAA AACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTA TCCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGT GCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCGGattacga catcccaacgaccgaaaacctgtattttcagggcG CT GACT C G AAT G G C AC G ATTAC C GT C GAG GAATTAAAAAAGTTATTGGAACAATGGAACCTGGTAATCGGCTTCCTGTTTCTTA CGTGGATTTGTTTGCTGCAATTTGCCTATGCTAACCGCAACCGTTTCTTATATAT TATTAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCATGTTTTGTT TTGGCTGCCGTCTATCGCATCAACTGGATTACCGGCGGAATCGCCATTGCTATG GCCTGTTTGGTTGGTCTGATGTGGCTGTCATACTTTATTGCCAGTTTTCGTTTGT TCGCCCGTACACGCTCTATGTGGAGCTTCAACCCAGAGACAAACATTCTGTTGA ATGTTCCTCTGCATGGCACCATTCTGACGCGTCCATTATTAGAGAGTGAATTAG TCATCGGAGCTGTTATTCTGCGCGGACACCTTCGTATCGCCGGTCATCACTTGG GTCGTTGCGACATCAAGGACTTACCAAAAGAAATTACAGTGGCTACATCACGCA CCCTTTCCTATTATAAATTGGGTGCCTCACAACGCGTTGCCGGAGATTCGGGAT TTGCTGCTTACTCACGTTACCGTATCGGAAATTACAAACTGAATACAGACCACTC TAGCTCATCCGATAACATTGCGCTTTTAGTGCAGTAActcgagccttaggagatccggctgct aacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0338] His-Spy-mCherry-TEV-POl

[0339] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA AAGattacgacatcccaacgaccgaaaacctgtattttcagggcCGCGACAAATTAAGCAGCACTA

[0340] ATCAGTTACGCAGTGTCGGATTGAACCTGGAGGGCAACGGCGTCGCCACAGAC

[0341] GTTCCGTCCGCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGG

[0342] TTGTTAATTATGAAGCTGGTGAATGGGCCGAAAATTGCTACAACTTAGAGATCAA

[0343] GAAGCCAGACGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGC

[0344] TTTCCTCGCTGCCGTTATGTTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGG

[0345] TGATTTCGCTTTTCACAAAGAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCA

[0346] ACGGTCATTTACCGCGGGACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAAT

[0347] TCTGCCCCAAGCTAAGAAGGATTTCTTCTCGTCACATCCTCTTCGTGAGTAActcg agccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTT ATTgcctcgg

[0348] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0349] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA

[0350] GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA

[0351] TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA

[0352] GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG

[0353] TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA

[0354] GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG

[0355] GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC

[0356] GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT

[0357] ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG

[0358] GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC

[0359] GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT

[0360] CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT

[0361] AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA

[0362] ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA

[0363] AAGattacgacatcccaacgaccgaaaacctgtattttcagggcATTCCTTTAGGTGTAATCCACAA

[0364] TAGCACACTTCAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCT

[0365] AGTACTAACCAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGC

[0366] CACGGATGTCCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTGGAGTGCCG

[0367] CCTAAAGTGGTCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGTTACAATTTA

[0368] GAGATTAAAAAACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCCGACGGTAT

[0369] CCGCGGATTTCCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACTGGTCCGT

[0370] GTGCAGGGGATTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTATGATCGTC

[0371] TTGCTTCCACCGTAATTTACCGTGGCACGACGTTTGCTGAGGGGGTGGTAGCG

[0372] TTCCTGATCCTGCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggagatccggctgcta acaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA AAGattacgacatcccaacgaccgaaaacctgtattttcagggcTTAAGTTCCACTAACCAGCTTCG TAGTGTAGGGTTAAACTTGGAAGGTAACGGAGTAGCTACGGATGTGCCTAGCG CTACGAAGCGTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTAC GAAGCAGGCGAATGGGCAGAAAATTGCTATAATCTGGAAATTAAAAAGCCTGAC GGCAGCGAATGTTTACCTGCCGCCCCGGACGGCATCCGTGGATTTCCACGTTG TCGCTACGTGCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTTAActcgagcctta ggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcc tcgg

[0373] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA AAGattacgacatcccaacgaccgaaaacctgtattttcagggcGAAGCCATCGTGAACGCCCAAC CCAAATGTAATCCAAATCTGCATTATTGGACAACACAAGATGAAGGGGCAGCTA TCGGCTTAGCCTGGATTCCGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTG AAGGCCTGATGCACAATCAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCC

[0374] AACGAAACTACTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGT ACATTCTCAATCTTAAACCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGA GGTACGTGCCACATTTTAGGTCCTGACTGCTGTATTGAACCACACGATTGGACT AAGAATATTACGGACAAGATCGACCAGATTATTCATGATTTTGTTGATAAGACGT

[0375] TACCGGATCAGGGTGACAATGATAATTGGTGGACGGGCTGGCGTTAActcgagcctt aggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgc ctcgg

[0376] 5. MERS CoV RBD 367-606

[0377] AATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatctcgatccc gcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaagaaggaga tataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACCGACTAT TGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAAGGGGG

[0378] AAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCATATGG AAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAAGGACG CCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGGTCCGTT GCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAAGGCTTA

[0379] TGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCGGAAGG GTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTACGGTCA CTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTTACGTG GAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGGGCTGG

[0380] GAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGCGAGAT

[0381] CAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGTCAAAA CTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGTAAACA TTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACAATATG AACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATAAAGatt acgacatcccaacgaccgaaaacctgtattttcagggcGAAGCCAAACCCAGTGGAAGCGTCGT GGAACAGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGACAC CCCCGCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAATCT TACCAAATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCTC

[0382] CGGCCGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTTA TCCCCTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTCGCA ATTTAACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACCGTA CCTCATAATTTAACGACGATCACCAAGCCACTGAAGTACAGCTATATTAATAAAT

[0383] GCAGTCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCAATTGGTTAATGCG AACCAATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGATGGT

[0384] GATTACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGGC AAGTGGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGGGCTTCGGCATTAC AGTTCAATATGGTACTGACACGAACAGTGTATGCCCTAAGATTGAATTTGCGAAT GACACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATATTAActcgagccttagga gatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcg g

[0385] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA AAGattacgacatcccaacgaccgaaaacctgtattttcagggcTACGTTGATGTCGGTCCAGACT CGGTAAAAAGTGCTTGCATTGAAGTGGACATTCAACAGACCTTCTTCGATAAAA CTTGGCCTCGTCCTATCGATGTTAGCAAGGCGGATGGCATCATCTATCCTCAGG GCCGCACATATTCGAACATTACCATCACATATCAGGGCTTGTTTCCTTACCAAG GCGACCATGGTGATATGTACGTTTATTCTGCTGGACACGCGACTGGTACTACCC CTCAGAAACTGTTTGTTGCGAACTACTCTCAAGACGTGAAGCAATTTGCGAATG GGTTCGTAGTTCGCATTGGGGCAGCGGCGAACTCAACTGGGACAGTGATTATT TCGCCCAGTACATCGGCGACGATTCGTAAGATTTATCCAGCCTTCATGTTAGGG TCGTCCGTGGGTAACTTTAGCGACGGGAAGATGGGGCGTTTTTTCAACCACAC CCTGGTGTTGTTGCCGGATGGTTGCGGTACCTTACTTCGCGCTTTTTATTGTATT TTAGAGCCCCGCTCTGGTAACCACTGTCCCGCGGGTAACTCATACACATCTTTT GCCACTTACCACACCCCCGCGACAGACTGCAGCGATGGTAACTATAATCGTAA CGCCTCCCTGAACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGCACCTTCATG TATACTTACAATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTATTACTCAAA CCGCGCAGGGGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTTATGGAGGTA ACATGTTCCAGTTTGCTACGTTGCCGGTCTACGATACTATCAAGTATTATTCAAT CATTCCGCATTCGATCCGTTCAATCCAGAGTGATCGTAAGGCGTGGGCGGCGT TCTACGTCTATAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTAGTGTGGATG GCTATATTCGCCGTGCGATTGACTGTGGGTTCAATGACTTGAGTCAATTACATT GTAGTTACGAATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagC ACTTTAGTTACAACATACTTATTgcctcgg

[0386] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0387] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA

[0388] GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA

[0389] TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA

[0390] GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG

[0391] TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA

[0392] GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG

[0393] GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC

[0394] GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT

[0395] ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG

[0396] GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC

[0397] GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT

[0398] CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT

[0399] AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA

[0400] ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA

[0401] AAGattacgacatcccaacgaccgaaaacctgtattttcagggcAATATTACTAATCTGTGTCCATT

[0402] CGGCGAGGTTTTTAACGCGACACGTTTTGCGAGTGTTTACGCATGGAATCGCAA

[0403] ACGTATTAGTAATTGCGTCGCCGACTATTCGGTTTTATATAACTCAGCGTCTTTC

[0404] AGCACTTTCAAATGTTATGGAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTA

[0405] CGAACGTCTACGCTGACAGCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCG

[0406] CTCCAGGACAGACCGGAAAGATCGCCGATTACAACTATAAATTGCCTGACGATT

[0407] TCACGGGATGCGTTATTGCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGC

[0408] GGTAACTATAACTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTG

[0409] AACGTGATATTTCCACAGAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGG

[0410] GTGGAGGGGTTTAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGA

[0411] ATGGCGTGGGTTATCAACCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGC

[0412] ATGCTCCCGCTACAGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagct gagCACTTTAGTTACAACATACTTATTgcctcgg

[0413] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0414] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA

[0415] GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA

[0416] TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA

[0417] GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG

[0418] TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA

[0419] GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG

[0420] GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC

[0421] GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT

[0422] ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG

[0423] GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC

[0424] GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT

[0425] AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA

[0426] ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA

[0427] AAGattacgacatcccaacgaccgaaaacctgtattttcagggcAGTGACAACGGACCCCAAAATC

[0428] AGCGCAATGCGCCGCGTATTACGTTCGGTGGGCCATCAGACTCTACGGGCTCA

[0429] AATCAAAATGGCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGG

[0430] TTTACCCAATAACACCGCATCTTGGTTCACGGCCCTTACACAGCATGGTAAAGA

[0431] GGACCTGAAGTTCCCCCGCGGACAAGGTGTCCCTATCAATACCAATTCAAGCC

[0432] CTGACGATCAAATCGGTTACTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTG

[0433] ACGGGAAGATGAAGGACTTGTCACCGCGCTGGTACTTTTATTACTTAGGGACAG

[0434] GCCCAGAGGCAGGATTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTC

[0435] GCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCC

[0436] AGCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGA

[0437] AAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGC

[0438] TCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGG

[0439] ACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATT

[0440] GCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAAC

[0441] AACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAG

[0442] CCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGT

[0443] CGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCG

[0444] CCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGG

[0445] CAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAA

[0446] CGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTA

[0447] AAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCC

[0448] AACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGC

[0449] CTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTG

[0450] GATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAA

[0451] GCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTAC AACATACTTATTgcctcgg

[0452] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0453] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA

[0454] GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA

[0455] TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA

[0456] GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG

[0457] TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA

[0458] GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG

[0459] GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC

[0460] GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT

[0461] ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG

[0462] GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC

[0463] GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT

[0464] AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA

[0465] ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA

[0466] AAGattacgacatcccaacgaccgaaaacctgtattttcagggcTTGCCGTATGGAGCGAATAAGG

[0467] ACGGAATCATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCAC

[0468] ATCGGCACCCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAG

[0469] GGCACGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCA

[0470] AGCCTCCTCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCC

[0471] TGGCTCTTCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGAT

[0472] GCAGCCCTGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATG

[0473] TCAGGAAAAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGC

[0474] GGAAGCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATG

[0475] TTACACAGGCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGA

[0476] GACCAAGAACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCA

[0477] CAGTTTGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAA

[0478] GTCACTCCCAGCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGA

[0479] CAAGGACCCTAATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCG

[0480] TACAAAACTTTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGAC

[0481] GAAACCCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCT GCCGGCCGCCGACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTC CGCTGATTCAACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaa gctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0482] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC

[0483] GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA

[0484] GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA

[0485] TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA

[0486] GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG

[0487] TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT

[0488] ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG

[0489] GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC

[0490] GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT

[0491] CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT

[0492] AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA

[0493] ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA

[0494] AAGattacgacatcccaacgaccgaaaacctgtattttcagggcTATTCATTTGTCTCTGAGGAGAC TGGTACCTTAATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGC TGGTCACTTTGGCGATTTTGACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATAT CGTCAACGTGTCTCTGGTAAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAAC CTTAATAGCTCCCGCGTCCCCGATCTGTTGGTCTAActcgagccttaggagatccggctgct aacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0495] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCGTCTCAAA

[0496] GGGGGAAGAGGATAATATGGCGATCATCAAGGAGTTTATGCGTTTCAAAGTTCA TATGGAAGGCAGTGTTAACGGCCACGAGTTCGAGATTGAGGGGGAGGGGGAA GGACGCCCTTACGAAGGGACCCAAACAGCTAAATTAAAAGTGACTAAAGGGGG TCCGTTGCCTTTCGCGTGGGATATCTTATCACCGCAGTTCATGTATGGATCGAA GGCTTATGTAAAACACCCCGCAGACATCCCTGATTACCTTAAACTTTCATTCCCG

[0497] GAAGGGTTTAAATGGGAGCGTGTAATGAATTTTGAGGACGGAGGGGTAGTTAC GGTCACTCAAGATAGCAGTTTACAAGATGGAGAGTTCATTTATAAGGTGAAGTT ACGTGGAACAAACTTCCCGTCAGACGGTCCCGTTATGCAAAAAAAGACGATGG GCTGGGAGGCTTCTTCCGAGCGCATGTATCCAGAAGACGGTGCACTGAAAGGC GAGATCAAGCAACGCCTGAAATTAAAGGACGGGGGACATTATGACGCCGAGGT

[0498] CAAAACTACATACAAAGCTAAGAAACCCGTTCAGTTACCAGGTGCCTACAACGT AAACATTAAATTGGACATTACGTCGCATAACGAGGATTACACGATCGTGGAACA ATATGAACGTGCTGAGGGTCGCCACTCCACCGGGGGTATGGACGAGCTTTATA AAGattacgacatcccaacgaccgaaaacctgtattttcagggcGCTGACTCGAATGGCACGATTA CCGTCGAGGAATTAAAAAAGTTATTGGAACAATGGAACCTGGTAATCGGCTTCC

[0499] TGTTTCTTACGTGGATTTGTTTGCTGCAATTTGCCTATGCTAACCGCAACCGTTT CTTATATATTATTAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCA TGTTTTGTTTTGGCTGCCGTCTATCGCATCAACTGGATTACCGGCGGAATCGCC ATTGCTATGGCCTGTTTGGTTGGTCTGATGTGGCTGTCATACTTTATTGCCAGTT TTCGTTTGTTCGCCCGTACACGCTCTATGTGGAGCTTCAACCCAGAGACAAACA

[0500] TTCTGTTGAATGTTCCTCTGCATGGCACCATTCTGACGCGTCCATTATTAGAGA GTGAATTAGTCATCGGAGCTGTTATTCTGCGCGGACACCTTCGTATCGCCGGTC ATCACTTGGGTCGTTGCGACATCAAGGACTTACCAAAAGAAATTACAGTGGCTA CATCACGCACCCTTTCCTATTATAAATTGGGTGCCTCACAACGCGTTGCCGGAG ATTCGGGATTTGCTGCTTACTCACGTTACCGTATCGGAAATTACAAACTGAATAC

[0501] AGACCACTCTAGCTCATCCGATAACATTGCGCTTTTAGTGCAGTAActcgagccttag gagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcct egg

[0502] His-Spy-NusA-TEV-POl

[0503] 1 . EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggc

[0504] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcCGCGACAAATTAAGCAGCACTAAT CAGTTACGCAGTGTCGGATTGAACCTGGAGGGCAACGGCGTCGCCACAGACGT TCCGTCCGCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGGTT GTTAATTATGAAGCTGGTGAATGGGCCGAAAATTGCTACAACTTAGAGATCAAG AAGCCAGACGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGCT TTCCTCGCTGCCGTTATGTTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGGT GATTTCGCTTTTCACAAAGAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCAA CGGTCATTTACCGCGGGACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAATT CTGCCCCAAGCTAAGAAGGATTTCTTCTCGTCACATCCTCTTCGTGAGTAActcga gccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTA TTgcctcgg

[0505] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcATTCCTTTAGGTGTAATCCACAAT AGCACACTTCAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCT AGTACTAACCAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGC CACGGATGTCCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTGGAGTGCCG CCTAAAGTGGTCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGTTACAATTTA GAGATTAAAAAACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCCGACGGTAT CCGCGGATTTCCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACTGGTCCGT GTGCAGGGGATTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTATGATCGTC TTGCTTCCACCGTAATTTACCGTGGCACGACGTTTGCTGAGGGGGTGGTAGCG TTCCTGATCCTGCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggagatccggctgcta acaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0506] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcTTAAGTTCCACTAACCAGCTTCGT AGTGTAGGGTTAAACTTGGAAGGTAACGGAGTAGCTACGGATGTGCCTAGCGC TACGAAGCGTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTACG AAGCAGGCGAATGGGCAGAAAATTGCTATAATCTGGAAATTAAAAAGCCTGACG GCAGCGAATGTTTACCTGCCGCCCCGGACGGCATCCGTGGATTTCCACGTTGT CGCTACGTGCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTTAActcgagccttag gagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcct egg

[0507] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcGAAGCCATCGTGAACGCCCAACC CAAATGTAATCCAAATCTGCATTATTGGACAACACAAGATGAAGGGGCAGCTAT CGGCTTAGCCTGGATTCCGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTG AAGGCCTGATGCACAATCAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCC AACGAAACTACTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGT ACATTCTCAATCTTAAACCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGA GGTACGTGCCACATTTTAGGTCCTGACTGCTGTATTGAACCACACGATTGGACT AAGAATATTACGGACAAGATCGACCAGATTATTCATGATTTTGTTGATAAGACGT TACCGGATCAGGGTGACAATGATAATTGGTGGACGGGCTGGCGTTAActcgagcctt aggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgc ctcgg

[0508] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcGAAGCCAAACCCAGTGGAAGCGT CGTGGAACAGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGA CACCCCCGCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAA TCTTACCAAATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTT CTCCGGCCGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTC TTATCCCCTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTC GCAATTTAACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACC GTACCTCATAATTTAACGACGATCACCAAGCCACTGAAGTACAGCTATATTAATA AATGCAGTCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCAATTGGTTAAT GCGAACCAATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGAT GGTGATTACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGT GGCAAGTGGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGGGCTTCGGCA TTACAGTTCAATATGGTACTGACACGAACAGTGTATGCCCTAAGATTGAATTTGC GAATGACACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATATTAActcgagcct taggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTg cctcgg

[0509] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcT ACGTT GAT GT C GGTCCAGACT C GGTAAAAAGTGCTTGCATTGAAGTGGACATTCAACAGACCTTCTTCGATAAAACT TGGCCTCGTCCTATCGATGTTAGCAAGGCGGATGGCATCATCTATCCTCAGGG CCGCACATATTCGAACATTACCATCACATATCAGGGCTTGTTTCCTTACCAAGG CGACCATGGTGATATGTACGTTTATTCTGCTGGACACGCGACTGGTACTACCCC TCAGAAACTGTTTGTTGCGAACTACTCTCAAGACGTGAAGCAATTTGCGAATGG GTTCGTAGTTCGCATTGGGGCAGCGGCGAACTCAACTGGGACAGTGATTATTT CGCCCAGTACATCGGCGACGATTCGTAAGATTTATCCAGCCTTCATGTTAGGGT CGTCCGTGGGTAACTTTAGCGACGGGAAGATGGGGCGTTTTTTCAACCACACC CTGGTGTTGTTGCCGGATGGTTGCGGTACCTTACTTCGCGCTTTTTATTGTATTT TAGAGCCCCGCTCTGGTAACCACTGTCCCGCGGGTAACTCATACACATCTTTTG CCACTTACCACACCCCCGCGACAGACTGCAGCGATGGTAACTATAATCGTAAC GCCTCCCTGAACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGCACCTTCATGT ATACTTACAATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTATTACTCAAAC CGCGCAGGGGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTTATGGAGGTAA CATGTTCCAGTTTGCTACGTTGCCGGTCTACGATACTATCAAGTATTATTCAATC ATTCCGCATTCGATCCGTTCAATCCAGAGTGATCGTAAGGCGTGGGCGGCGTT CTACGTCTATAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTAGTGTGGATGG CTATATTCGCCGTGCGATTGACTGTGGGTTCAATGACTTGAGTCAATTACATTGT AGTTACGAATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCAC TTTAGTTACAACATACTTATTgcctcgg

[0510] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcAATATTACTAATCTGTGTCCATTC GGCGAGGTTTTTAACGCGACACGTTTTGCGAGTGTTTACGCATGGAATCGCAAA CGTATTAGTAATTGCGTCGCCGACTATTCGGTTTTATATAACTCAGCGTCTTTCA GCACTTTCAAATGTTATGGAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTAC GAACGTCTACGCTGACAGCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCGC TCCAGGACAGACCGGAAAGATCGCCGATTACAACTATAAATTGCCTGACGATTT CACGGGATGCGTTATTGCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGCG GTAACTATAACTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGA ACGTGATATTTCCACAGAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGGG TGGAGGGGTTTAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGAA TGGCGTGGGTTATCAACCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGCA TGCTCCCGCTACAGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctg agCACTTTAGTTACAACATACTTATTgcctcgg

[0511] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcAGTGACAACGGACCCCAAAATCA GCGCAATGCGCCGCGTATTACGTTCGGTGGGCCATCAGACTCTACGGGCTCAA ATCAAAATGGCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGGT TTACCCAATAACACCGCATCTTGGTTCACGGCCCTTACACAGCATGGTAAAGAG GACCTGAAGTTCCCCCGCGGACAAGGTGTCCCTATCAATACCAATTCAAGCCCT GACGATCAAATCGGTTACTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTGAC GGGAAGATGAAGGACTTGTCACCGCGCTGGTACTTTTATTACTTAGGGACAGG CCCAGAGGCAGGATTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCG CCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCA GCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAA AGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCT CATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGG ACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATT GCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAAC AACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAG CCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGT CGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCG CCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGG CAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAA CGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTA AAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCC AACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGC CTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTG GATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAA GCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTAC AACATACTTATTgcctcgg

[0512] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcTTGCCGTATGGAGCGAATAAGGA CGGAATCATCTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACA TCGGCACCCGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAG GGCACGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCA AGCCTCCTCCCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCC TGGCTCTTCCCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGAT GCAGCCCTGGCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATG TCAGGAAAAGGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGC GGAAGCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATG TTACACAGGCATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGA GACCAAGAACTTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCA CAGTTTGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAA GTCACTCCCAGCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGA CAAGGACCCTAATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCG TACAAAACTTTTCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGAC GAAACCCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCT GCCGGCCGCCGACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTC CGCTGATTCAACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaa gctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0513] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcT ATT CATTT GT CT CT GAGGAGACT GGTACCTTAATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCT GGTCACTTTGGCGATTTTGACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATATC GTCAACGTGTCTCTGGTAAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAACC TTAATAGCTCCCGCGTCCCCGATCTGTTGGTCTAActcgagccttaggagatccggctgctaa caaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg His-Spy-Sortase-TEV-POl

[0514] I .EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCaacaaagaaat tttggctgtagttgaagccgtatccaatgaaaaggcgctacctcgcgagaagattttcgaagcattggaaagcgcgct ggcgacagcaacaaagaaaaaatatgaacaagagatcgacgtccgcgtacagatcgatcgcaaaagcggtgatt ttgacactttccgtcgctggttagttgttgatgaagtcacccagccgaccaaggaaatcacccttgaagccgcacgttat gaagatgaaagcctgaacctgggcgattacgttgaagatcagattgagtctgttacctttgaccgtatcactacccaga cggcaaaacaggttatcgtgcagaaagtgcgtgaagccgaacgtgcgatggtggttgatcagttccgtgaacacga aggtgaaatcatcaccggcgtggtgaaaaaagtaaaccgcgacaacatctctctggatctgggcaacaacgctga agccgtgatcctgcgcgaagatatgctgccgcgtgaaaacttccgccctggcgaccgcgttcgtggcgtgctctattcc gttcgcccggaagcgcgtggcgcgcaactgttcgtcactcgttccaagccggaaatgctgatcgaactgttccgtattg aagtgccagaaatcggcgaagaagtgattgaaattaaagcagcggctcgcgatccgggttctcgtgcgaaaatcgc ggtgaaaaccaacgataaacgtatcgatccggtaggtgcttgcgtaggtatgcgtggcgcgcgtgttcaggcggtgtc tactgaactgggtggcgagcgtatcgatatcgtcctgtgggatgataacccggcgcagttcgtgattaacgcaatggc accggcagacgttgcttctatcgtggtggatgaagataaacacaccatggatatcgccgttgaagccggtaacctggc gcaggcgattggccgtaacggtcagaacgtgcgtctggcttcgcagctgagcggttgggaactcaacgtgatgaccg ttgacgacctgcaggctaagcatcaggcggaagcgcacgcagcgatcgacaccttcaccaaatatctcgacatcga cgaagacttcgcgactgttctggtagaagaaggcttctcgacgctggaagaattggcctatgtgccgatgaaagagct gttggaaatcgaaggccttgatgagccgaccgttgaagcactgcgcgagcgtgctaaaaatgcactggccaccattg cacaggcccaggaagaaagcctcggtgataacaaaccggctgacgatctgctgaaccttgaaggggtagatcgtg atttggcattcaaactggccgcccgtggcgtttgtacgctggaagatctcgccgaacagggcattgatgatctggctgat atcgaagggttgaccgacgaaaaagccggagcactgattatggctgcccgtaacatttgctggttcggtgacgaagc gGattacgacatcccaacgaccgaaaacctgtattttcagggcGCTGACTCGAATGGCACGATTAC CGTCGAGGAATTAAAAAAGTTATTGGAACAATGGAACCTGGTAATCGGCTTCCT GTTTCTTACGTGGATTTGTTTGCTGCAATTTGCCTATGCTAACCGCAACCGTTTC TTATATATTATTAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCAT GTTTTGTTTTGGCTGCCGTCTATCGCATCAACTGGATTACCGGCGGAATCGCCA TTGCTATGGCCTGTTTGGTTGGTCTGATGTGGCTGTCATACTTTATTGCCAGTTT TCGTTTGTTCGCCCGTACACGCTCTATGTGGAGCTTCAACCCAGAGACAAACAT TCTGTTGAATGTTCCTCTGCATGGCACCATTCTGACGCGTCCATTATTAGAGAG TGAATTAGTCATCGGAGCTGTTATTCTGCGCGGACACCTTCGTATCGCCGGTCA TCACTTGGGTCGTTGCGACATCAAGGACTTACCAAAAGAAATTACAGTGGCTAC ATCACGCACCCTTTCCTATTATAAATTGGGTGCCTCACAACGCGTTGCCGGAGA TTCGGGATTTGCTGCTTACTCACGTTACCGTATCGGAAATTACAAACTGAATACA GACCACTCTAGCTCATCCGATAACATTGCGCTTTTAGTGCAGTAActcgagccttagga gatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcg g

[0515] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcATTCCTTTAGGTGTAATCCACAATAGCACACTTCAGGTAAGTGACG TAGATAAACTTGTCTGTCGTGATAAGTTGTCTAGTACTAACCAACTGCGTTCTGT CGGGCTTAACCTTGAGGGGAATGGAGTCGCCACGGATGTCCCGTCGGCAACG AAACGCTGGGGATTTCGCTCTGGAGTGCCGCCTAAAGTGGTCAACTATGAAGC AGGCGAGTGGGCGGAGAATTGTTACAATTTAGAGATTAAAAAACCAGACGGGT CTGAGTGCTTACCTGCCGCGCCCGACGGTATCCGCGGATTTCCACGCTGTCGC TATGTGCACAAAGTTAGTGGTACTGGTCCGTGTGCAGGGGATTTCGCATTTCAC AAAGAAGGAGCCTTCTTTCTTTATGATCGTCTTGCTTCCACCGTAATTTACCGTG

[0516] GCACGACGTTTGCTGAGGGGGTGGTAGCGTTCCTGATCCTGCCGCAAGCAAAA AAGGACTTTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTT AGTTACAACATACTTATTgcctcgg

[0517] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcTTAAGTTCCACTAACCAGCTTCGTAGTGTAGGGTTAAACTTGGAAG GTAACGGAGTAGCTACGGATGTGCCTAGCGCTACGAAGCGTTGGGGGTTTCGT AGCGGTGTTCCTCCCAAAGTGGTGAACTACGAAGCAGGCGAATGGGCAGAAAA TTGCTATAATCTGGAAATTAAAAAGCCTGACGGCAGCGAATGTTTACCTGCCGC CCCGGACGGCATCCGTGGATTTCCACGTTGTCGCTACGTGCATAAGGTATCAG GCACCGGCCCTTGTGCGGGTTAActcgagccttaggagatccggctgctaacaaagcccgaaagg aagctgagCACTTTAGTTACAACATACTTATTgcctcgg 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcGAAGCCATCGTGAACGCCCAACCCAAATGTAATCCAAATCTGCATT ATTGGACAACACAAGATGAAGGGGCAGCTATCGGCTTAGCCTGGATTCCGTATT TTGGGCCTGCCGCGGAGGGGATTTATATTGAAGGCCTGATGCACAATCAGGAC GGTTTGATCTGCGGCTTGCGCCAGTTAGCCAACGAAACTACTCAAGCCTTGCA GCTGTTCCTGCGCGCTACGACCGAATTGCGTACATTCTCAATCTTAAACCGCAA AGCAATCGACTTCTTACTTCAGCGTTGGGGAGGTACGTGCCACATTTTAGGTCC TGACTGCTGTATTGAACCACACGATTGGACTAAGAATATTACGGACAAGATCGA CCAGATTATTCATGATTTTGTTGATAAGACGTTACCGGATCAGGGTGACAATGAT AATTGGTGGACGGGCTGGCGTTAActcgagccttaggagatccggctgctaacaaagcccgaaag gaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0518] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcGAAGCCAAACCCAGTGGAAGCGTCGTGGAACAGGCAGAAGGTGT GGAGTGCGATTTCTCACCGCTGCTGTCCGGGACACCCCCGCAAGTGTATAACT TCAAACGTTTAGTGTTTACTAACTGTAACTATAATCTTACCAAATTGCTGTCTCTG TTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCTCCGGCCGCGATCGCTTCTA ATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTTATCCCCTTTCCATGAAAAGT GATTTAAGCGTCAGCTCCGCAGGACCGATCTCGCAATTTAACTATAAACAGTCG TTTAGCAATCCAACGTGTTTAATTCTGGCAACCGTACCTCATAATTTAACGACGA TCACCAAGCCACTGAAGTACAGCTATATTAATAAATGCAGTCGTTTGCTGTCGG ACGACCGCACGGAAGTACCCCAATTGGTTAATGCGAACCAATACTCTCCCTGC GTTTCAATTGTACCCTCGACTGTTTGGGAGGATGGTGATTACTACCGCAAACAA CTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGGCAAGTGGTTCTACGGTTGC AATGACCGAGCAATTGCAAATGGGCTTCGGCATTACAGTTCAATATGGTACTGA CACGAACAGTGTATGCCCTAAGATTGAATTTGCGAATGACACTAAAATTGCCTC GCAATTAGGAAACTGTGTCGAATATTAActcgagccttaggagatccggctgctaacaaagcccg aaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0519] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcTACGTTGATGTCGGTCCAGACTCGGTAAAAAGTGCTTGCATTGAAG TGGACATTCAACAGACCTTCTTCGATAAAACTTGGCCTCGTCCTATCGATGTTAG CAAGGCGGATGGCATCATCTATCCTCAGGGCCGCACATATTCGAACATTACCAT CACATATCAGGGCTTGTTTCCTTACCAAGGCGACCATGGTGATATGTACGTTTA TTCTGCTGGACACGCGACTGGTACTACCCCTCAGAAACTGTTTGTTGCGAACTA CTCTCAAGACGTGAAGCAATTTGCGAATGGGTTCGTAGTTCGCATTGGGGCAG CGGCGAACTCAACTGGGACAGTGATTATTTCGCCCAGTACATCGGCGACGATT CGTAAGATTTATCCAGCCTTCATGTTAGGGTCGTCCGTGGGTAACTTTAGCGAC GGGAAGATGGGGCGTTTTTTCAACCACACCCTGGTGTTGTTGCCGGATGGTTG CGGTACCTTACTTCGCGCTTTTTATTGTATTTTAGAGCCCCGCTCTGGTAACCAC TGTCCCGCGGGTAACTCATACACATCTTTTGCCACTTACCACACCCCCGCGACA GACTGCAGCGATGGTAACTATAATCGTAACGCCTCCCTGAACTCGTTTAAAGAG TATTTCAATCTGCGCAATTGCACCTTCATGTATACTTACAATATTACAGAGGATG AGATCTTAGAGTGGTTCGGTATTACTCAAACCGCGCAGGGGGTCCACTTGTTTT CGTCACGTTATGTGGATCTTTATGGAGGTAACATGTTCCAGTTTGCTACGTTGC CGGTCTACGATACTATCAAGTATTATTCAATCATTCCGCATTCGATCCGTTCAAT CCAGAGTGATCGTAAGGCGTGGGCGGCGTTCTACGTCTATAAACTTCAGCCGC

[0520] TGACCTTCCTGTTGGACTTTAGTGTGGATGGCTATATTCGCCGTGCGATTGACT GTGGGTTCAATGACTTGAGTCAATTACATTGTAGTTACGAATCTTAActcgagccttag gagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcct egg

[0521] 7. SARS CoV-2 RBD 331-524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcAATATTACTAATCTGTGTCCATTCGGCGAGGTTTTTAACGCGACAC GTTTTGCGAGTGTTTACGCATGGAATCGCAAACGTATTAGTAATTGCGTCGCCG ACTATTCGGTTTTATATAACTCAGCGTCTTTCAGCACTTTCAAATGTTATGGAGTT AGTCCAACGAAGTTGAATGATCTTTGTTTTACGAACGTCTACGCTGACAGCTTC GTTATCCGTGGTGATGAAGTACGTCAAATCGCTCCAGGACAGACCGGAAAGAT CGCCGATTACAACTATAAATTGCCTGACGATTTCACGGGATGCGTTATTGCGTG GAACTCGAACAATCTTGACTCGAAGGTGGGCGGTAACTATAACTACCTGTATCG TCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGAACGTGATATTTCCACAGAAATC TATCAGGCCGGCTCGACGCCGTGCAATGGGGTGGAGGGGTTTAATTGCTATTT TCCACTTCAGTCTTATGGTTTCCAGCCTACGAATGGCGTGGGTTATCAACCCTA CCGCGTAGTCGTGTTATCATTCGAGTTGCTGCATGCTCCCGCTACAGTCTAActc gagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACT TATTgcctcgg

[0522] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcAGTGACAACGGACCCCAAAATCAGCGCAATGCGCCGCGTATTACG TTCGGTGGGCCATCAGACTCTACGGGCTCAAATCAAAATGGCGAGCGCTCGGG CGCTCGTAGCAAGCAACGCCGTCCTCAAGGTTTACCCAATAACACCGCATCTTG GTTCACGGCCCTTACACAGCATGGTAAAGAGGACCTGAAGTTCCCCCGCGGAC AAGGTGTCCCTATCAATACCAATTCAAGCCCTGACGATCAAATCGGTTACTACC GTCGTGCTACTCGTCGTATCCGTGGTGGTGACGGGAAGATGAAGGACTTGTCA CCGCGCTGGTACTTTTATTACTTAGGGACAGGCCCAGAGGCAGGATTGCCGTA TGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACGGAGGGAGCCTTGAACA CTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAATAACGCGGCAATCGTG TTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCTTCTATGCCGAAGGCTC TCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCACGCTCTCGCAACTCCT CCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTCGCCTGCACGCATGGCT GGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGTTAGACCGCTTGAACCA

[0523] ACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAACAAGGTCAAACCGTAAC AAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTCAAAAGCGTACAGCGA CCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGCGGTCCTGAGCAGACC CAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGGCACAGACTATAAGCAC TGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTGCTTTCTTCGGAATGTCA CGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGTTGACCTACACTGGTGC GATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATCAGGTCATTTTACTTAAT AAACATATCGACGCGTACAAAACTTTTCCTCCAACTGAACCTAAGAAAGATAAGA AGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAACGCCAGAAAAAGCAGCAG ACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGACTTCTCTAAACAGCTTCA GCAATCTATGAGTTCCGCTGATTCAACCCAAGCCTAActcgagccttaggagatccggctgc taacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0524] 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcTTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACG GAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAA TAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCT TCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCA CGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTC GCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGT TAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAAC AAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGT CAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGC GGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGG CACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTG CTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGT TGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATC AGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCAACTGA ACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAAC

[0525] GCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGAC TTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGCCTAAct cgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATAC TTATTgcctcgg

[0526] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcTATTCATTTGTCTCTGAGGAGACTGGTACCTTAATCGTCAATTCAGT GCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCTGGTCACTTTGGCGATTTTGACC GCGTTGCGTTTGTGTGCTTACTGTTGTAATATCGTCAACGTGTCTCTGGTAAAAC CATCTTTCTATGTCTATTCCCGCGTAAAAAACCTTAATAGCTCCCGCGTCCCCGA TCTGTTGGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTT TAGTTACAACATACTTATTgcctcgg

[0527] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCcaagctaaacc tcaaattccgaaagataaatcaaaagtggcaggctatattgaaattccagatgctgatattaaagaaccagtatatcc aggaccagcaacacgcgaacaattaaatagaggtgtaagctttgcagaagaaaatgaatcactagatgatcaaaa tatttcaattgcaggacacactttcattgaccgtccgaactatcaatttacaaatcttaaagcagccaaaaaaggtagta tggtgtactttaaagttggtaatgaaacacgtaagtataaaatgacaagtataagaaacgttaagccaacagctgtag aagttctagatgaacaaaaaggtaaagataaacaattaacattaattacttgtgatgattacaatgaagagacaggc gtttgggaaacacgtaaaatctttgtagctacagaagtcaaactcgagGattacgacatcccaacgaccgaaaacct gtattttcagggcGCTGACTCGAATGGCACGATTACCGTCGAGGAATTAAAAAAGTTAT TGGAACAATGGAACCTGGTAATCGGCTTCCTGTTTCTTACGTGGATTTGTTTGCT GCAATTTGCCTATGCTAACCGCAACCGTTTCTTATATATTATTAAACTGATCTTCT TGTGGCTGCTTTGGCCGGTAACATTAGCATGTTTTGTTTTGGCTGCCGTCTATC GCATCAACTGGATTACCGGCGGAATCGCCATTGCTATGGCCTGTTTGGTTGGTC TGATGTGGCTGTCATACTTTATTGCCAGTTTTCGTTTGTTCGCCCGTACACGCTC TATGTGGAGCTTCAACCCAGAGACAAACATTCTGTTGAATGTTCCTCTGCATGG CACCATTCTGACGCGTCCATTATTAGAGAGTGAATTAGTCATCGGAGCTGTTATT CTGCGCGGACACCTTCGTATCGCCGGTCATCACTTGGGTCGTTGCGACATCAA GGACTTACCAAAAGAAATTACAGTGGCTACATCACGCACCCTTTCCTATTATAAA TTGGGTGCCTCACAACGCGTTGCCGGAGATTCGGGATTTGCTGCTTACTCACG TTACCGTATCGGAAATTACAAACTGAATACAGACCACTCTAGCTCATCCGATAAC ATTGCGCTTTTAGTGCAGTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagc tgagCACTTTAGTTACAACATACTTATTgcctcgg

[0528] His-Spy-GST-TEV-POl

[0529] 1. EboV RBD 54-201 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcCGCGACAAATTAAGCAGCACTAATCAGTTACG CAGTGTCGGATTGAACCTGGAGGGCAACGGCGTCGCCACAGACGTTCCGTCC GCCACGAAGCGTTGGGGATTCCGTAGCGGGGTGCCTCCGAAGGTTGTTAATTA TGAAGCTGGTGAATGGGCCGAAAATTGCTACAACTTAGAGATCAAGAAGCCAGA CGGTTCAGAGTGTCTGCCAGCCGCGCCAGACGGGATTCGCGGCTTTCCTCGCT GCCGTTATGTTCACAAGGTTAGCGGGACGGGGCCGTGTGCCGGTGATTTCGCT TTTCACAAAGAGGGGGCTTTCTTCTTATACGACCGTTTAGCGTCAACGGTCATTT ACCGCGGGACAACGTTCGCGGAAGGAGTGGTGGCGTTCTTAATTCTGCCCCAA GCTAAGAAGGATTTCTTCTCGTCACATCCTCTTCGTGAGTAActcgagccttaggagatc cggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0530] 2. EboV RBD 33-193 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcATT C CTTTAG GT GT AAT C C AC AATAG C AC ACTT CAGGTAAGTGACGTAGATAAACTTGTCTGTCGTGATAAGTTGTCTAGTACTAAC CAACTGCGTTCTGTCGGGCTTAACCTTGAGGGGAATGGAGTCGCCACGGATGT CCCGTCGGCAACGAAACGCTGGGGATTTCGCTCTGGAGTGCCGCCTAAAGTGG TCAACTATGAAGCAGGCGAGTGGGCGGAGAATTGTTACAATTTAGAGATTAAAA AACCAGACGGGTCTGAGTGCTTACCTGCCGCGCCCGACGGTATCCGCGGATTT CCACGCTGTCGCTATGTGCACAAAGTTAGTGGTACTGGTCCGTGTGCAGGGGA TTTCGCATTTCACAAAGAAGGAGCCTTCTTTCTTTATGATCGTCTTGCTTCCACC GTAATTTACCGTGGCACGACGTTTGCTGAGGGGGTGGTAGCGTTCCTGATCCT GCCGCAAGCAAAAAAGGACTTTTAActcgagccttaggagatccggctgctaacaaagcccgaaa ggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0531] 3. EboV RBD 57-149 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcTTAAGTTCCACTAACCAGCTTCGTAGTGTAGG GTTAAACTTGGAAGGTAACGGAGTAGCTACGGATGTGCCTAGCGCTACGAAGC GTTGGGGGTTTCGTAGCGGTGTTCCTCCCAAAGTGGTGAACTACGAAGCAGGC GAATGGGCAGAAAATTGCTATAATCTGGAAATTAAAAAGCCTGACGGCAGCGAA TGTTTACCTGCCGCCCCGGACGGCATCCGTGGATTTCCACGTTGTCGCTACGT GCATAAGGTATCAGGCACCGGCCCTTGTGCGGGTTAActcgagccttaggagatccggctg ctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0532] 4. EboV GP2 502-648 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcGAAGCCATCGTGAACGCCCAACCCAAATGTAA TCCAAATCTGCATTATTGGACAACACAAGATGAAGGGGCAGCTATCGGCTTAGC CTGGATTCCGTATTTTGGGCCTGCCGCGGAGGGGATTTATATTGAAGGCCTGAT GCACAATCAGGACGGTTTGATCTGCGGCTTGCGCCAGTTAGCCAACGAAACTA CTCAAGCCTTGCAGCTGTTCCTGCGCGCTACGACCGAATTGCGTACATTCTCAA TCTTAAACCGCAAAGCAATCGACTTCTTACTTCAGCGTTGGGGAGGTACGTGCC ACATTTTAGGTCCTGACTGCTGTATTGAACCACACGATTGGACTAAGAATATTAC GGACAAGATCGACCAGATTATTCATGATTTTGTTGATAAGACGTTACCGGATCA GGGTGACAATGATAATTGGTGGACGGGCTGGCGTTAActcgagccttaggagatccggctg ctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0533] 5. MERS CoV RBD 367-606 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcGAAGCCAAACCCAGTGGAAGCGTCGTGGAAC AGGCAGAAGGTGTGGAGTGCGATTTCTCACCGCTGCTGTCCGGGACACCCCC GCAAGTGTATAACTTCAAACGTTTAGTGTTTACTAACTGTAACTATAATCTTACCA AATTGCTGTCTCTGTTCTCTGTGAATGATTTTACTTGCTCTCAAATTTCTCCGGC CGCGATCGCTTCTAATTGTTACAGTAGTTTGATTCTTGACTATTTCTCTTATCCC CTTTCCATGAAAAGTGATTTAAGCGTCAGCTCCGCAGGACCGATCTCGCAATTT AACTATAAACAGTCGTTTAGCAATCCAACGTGTTTAATTCTGGCAACCGTACCTC ATAATTTAACGACGATCACCAAGCCACTGAAGTACAGCTATATTAATAAATGCAG TCGTTTGCTGTCGGACGACCGCACGGAAGTACCCCAATTGGTTAATGCGAACC AATACTCTCCCTGCGTTTCAATTGTACCCTCGACTGTTTGGGAGGATGGTGATT ACTACCGCAAACAACTGTCGCCCCTTGAGGGCGGTGGTTGGCTGGTGGCAAGT GGTTCTACGGTTGCAATGACCGAGCAATTGCAAATGGGCTTCGGCATTACAGTT CAATATGGTACTGACACGAACAGTGTATGCCCTAAGATTGAATTTGCGAATGAC ACTAAAATTGCCTCGCAATTAGGAAACTGTGTCGAATATTAActcgagccttaggagatcc ggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0534] 6. MERS CoV NTD 18-353 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcT AC GTT GAT GTC G GTC C AG ACT C G GT AAAAAG TGCTTGCATTGAAGTGGACATTCAACAGACCTTCTTCGATAAAACTTGGCCTCG TCCTATCGATGTTAGCAAGGCGGATGGCATCATCTATCCTCAGGGCCGCACATA TTCGAACATTACCATCACATATCAGGGCTTGTTTCCTTACCAAGGCGACCATGG TGATATGTACGTTTATTCTGCTGGACACGCGACTGGTACTACCCCTCAGAAACT GTTTGTTGCGAACTACTCTCAAGACGTGAAGCAATTTGCGAATGGGTTCGTAGT TCGCATTGGGGCAGCGGCGAACTCAACTGGGACAGTGATTATTTCGCCCAGTA CATCGGCGACGATTCGTAAGATTTATCCAGCCTTCATGTTAGGGTCGTCCGTGG GTAACTTTAGCGACGGGAAGATGGGGCGTTTTTTCAACCACACCCTGGTGTTGT TGCCGGATGGTTGCGGTACCTTACTTCGCGCTTTTTATTGTATTTTAGAGCCCC GCTCTGGTAACCACTGTCCCGCGGGTAACTCATACACATCTTTTGCCACTTACC ACACCCCCGCGACAGACTGCAGCGATGGTAACTATAATCGTAACGCCTCCCTG AACTCGTTTAAAGAGTATTTCAATCTGCGCAATTGCACCTTCATGTATACTTACA ATATTACAGAGGATGAGATCTTAGAGTGGTTCGGTATTACTCAAACCGCGCAGG GGGTCCACTTGTTTTCGTCACGTTATGTGGATCTTTATGGAGGTAACATGTTCCA GTTTGCTACGTTGCCGGTCTACGATACTATCAAGTATTATTCAATCATTCCGCAT TCGATCCGTTCAATCCAGAGTGATCGTAAGGCGTGGGCGGCGTTCTACGTCTA TAAACTTCAGCCGCTGACCTTCCTGTTGGACTTTAGTGTGGATGGCTATATTCG CCGTGCGATTGACTGTGGGTTCAATGACTTGAGTCAATTACATTGTAGTTACGA ATCTTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTA CAACATACTTATTgcctcgg

[0535] 7. SARS CoV-2 RBD 331 -524 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcAATATTACTAATCTGTGTCCATTCGGCGAGGTT TTTAACGCGACACGTTTTGCGAGTGTTTACGCATGGAATCGCAAACGTATTAGT AATTGCGTCGCCGACTATTCGGTTTTATATAACTCAGCGTCTTTCAGCACTTTCA AATGTTATGGAGTTAGTCCAACGAAGTTGAATGATCTTTGTTTTACGAACGTCTA CGCTGACAGCTTCGTTATCCGTGGTGATGAAGTACGTCAAATCGCTCCAGGACA GACCGGAAAGATCGCCGATTACAACTATAAATTGCCTGACGATTTCACGGGATG CGTTATTGCGTGGAACTCGAACAATCTTGACTCGAAGGTGGGCGGTAACTATAA CTACCTGTATCGTCTTTTCCGTAAGTCCAATTTGAAGCCCTTTGAACGTGATATT TCCACAGAAATCTATCAGGCCGGCTCGACGCCGTGCAATGGGGTGGAGGGGTT TAATTGCTATTTTCCACTTCAGTCTTATGGTTTCCAGCCTACGAATGGCGTGGGT TATCAACCCTACCGCGTAGTCGTGTTATCATTCGAGTTGCTGCATGCTCCCGCT ACAGTCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGT TACAACATACTTATTgcctcgg

[0536] 8. SARS CoV-2 NP 1 -419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcAGT G AC AAC G G AC C C C AAAAT C AG C G C AAT G C GCCGCGTATTACGTTCGGTGGGCCATCAGACTCTACGGGCTCAAATCAAAATG GCGAGCGCTCGGGCGCTCGTAGCAAGCAACGCCGTCCTCAAGGTTTACCCAAT AACACCGCATCTTGGTTCACGGCCCTTACACAGCATGGTAAAGAGGACCTGAA GTTCCCCCGCGGACAAGGTGTCCCTATCAATACCAATTCAAGCCCTGACGATCA AATCGGTTACTACCGTCGTGCTACTCGTCGTATCCGTGGTGGTGACGGGAAGA TGAAGGACTTGTCACCGCGCTGGTACTTTTATTACTTAGGGACAGGCCCAGAG GCAGGATTGCCGTATGGAGCGAATAAGGACGGAATCATCTGGGTCGCCACGGA GGGAGCCTTGAACACTCCCAAAGACCACATCGGCACCCGTAATCCAGCAAATA ACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACTCTGCCGAAAGGCTTC TATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTCCCGTAGCTCATCACG CTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTCCCGTGGGACCTCGC CTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTGGCGTTATTGCTGTTA GACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAAGGCCAACAACAACA AGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTCCAAAAAGCCTCGTC AAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGCATTTGGTCGTCGC GGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAACTTATTCGCCAAGG CACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCACCCTCGGCAAGTG CTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCAGCGGAACGTGGT TGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCTAATTTTAAAGATC AGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTTTCCTCCAACTGA ACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGGCATTGCCTCAAC GCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCCGACCTGGATGAC TTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCAACCCAAGCCTAAct cgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTTAGTTACAACATAC TTATTgcctcgg 9. SARS CoV-2 NP 121-419 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcTTGCCGTATGGAGCGAATAAGGACGGAATCAT CTGGGTCGCCACGGAGGGAGCCTTGAACACTCCCAAAGACCACATCGGCACC CGTAATCCAGCAAATAACGCGGCAATCGTGTTACAATTGCCACAGGGCACGACT CTGCCGAAAGGCTTCTATGCCGAAGGCTCTCGTGGTGGAAGCCAAGCCTCCTC CCGTAGCTCATCACGCTCTCGCAACTCCTCCCGTAACTCAACCCCTGGCTCTTC CCGTGGGACCTCGCCTGCACGCATGGCTGGCAACGGTGGCGATGCAGCCCTG GCGTTATTGCTGTTAGACCGCTTGAACCAACTGGAAAGTAAGATGTCAGGAAAA GGCCAACAACAACAAGGTCAAACCGTAACAAAGAAGTCAGCAGCGGAAGCGTC CAAAAAGCCTCGTCAAAAGCGTACAGCGACCAAAGCCTACAATGTTACACAGGC ATTTGGTCGTCGCGGTCCTGAGCAGACCCAGGGTAACTTTGGAGACCAAGAAC TTATTCGCCAAGGCACAGACTATAAGCACTGGCCCCAAATCGCACAGTTTGCAC CCTCGGCAAGTGCTTTCTTCGGAATGTCACGTATCGGAATGGAAGTCACTCCCA GCGGAACGTGGTTGACCTACACTGGTGCGATCAAGCTTGATGACAAGGACCCT AATTTTAAAGATCAGGTCATTTTACTTAATAAACATATCGACGCGTACAAAACTTT TCCTCCAACTGAACCTAAGAAAGATAAGAAGAAAAAGGCAGACGAAACCCAGG CATTGCCTCAACGCCAGAAAAAGCAGCAGACTGTCACTCTGCTGCCGGCCGCC GACCTGGATGACTTCTCTAAACAGCTTCAGCAATCTATGAGTTCCGCTGATTCA ACCCAAGCCTAActcgagccttaggagatccggctgctaacaaagcccgaaaggaagctgagCACTTT AGTTACAACATACTTATTgcctcgg

[0537] 10. SARS CoV-2 E 1-75 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcTATTCATTTGTCTCTGAGGAGACTGGTACCTTA ATCGTCAATTCAGTGCTTTTATTCTTAGCTTTTGTAGTGTTCTTGCTGGTCACTTT GGCGATTTTGACCGCGTTGCGTTTGTGTGCTTACTGTTGTAATATCGTCAACGT GTCTCTGGTAAAACCATCTTTCTATGTCTATTCCCGCGTAAAAAACCTTAATAGC TCCCGCGTCCCCGATCTGTTGGTCTAActcgagccttaggagatccggctgctaacaaagcccga aaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0538] 11 . SARS CoV-2 M 1 -222 ggctccgAATAAGTATGTTGTAACTAAAGTGcggccacgatgcgtccggcgtagaggatcgagatct cgatcccgcgaaattaatacgactcactatagggagaccacaacggtttccctctagaaataattttgtttaactttaag aaggagatataccATGTCAGGCGGTCATCATCATCACCACCATAGTGGTTCCGTACC GACTATTGTAATGGTTGATGCATACAAACGCTACAAAGGAAGTGGCtcccctatactag gttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatcttgaagaaaaatatgaagagcatttgt atgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattg atggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaacatgttgggtggttgtccaa aagagcgtgcagagatttcaatgcttgaaggagcggttttggatattagatacggtgtttcgagaattgcatatagtaaa gactttgaaactctcaaagttgattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaa catatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtg cctggatgcgttcccaaaattagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccag caagtatatagcatggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaaGattacgacat cccaacgaccgaaaacctgtattttcagggcGCTGACTCGAATGGCACGATTACCGTCGAGGA ATTAAAAAAGTTATTGGAACAATGGAACCTGGTAATCGGCTTCCTGTTTCTTACG TGGATTTGTTTGCTGCAATTTGCCTATGCTAACCGCAACCGTTTCTTATATATTAT TAAACTGATCTTCTTGTGGCTGCTTTGGCCGGTAACATTAGCATGTTTTGTTTTG GCTGCCGTCTATCGCATCAACTGGATTACCGGCGGAATCGCCATTGCTATGGC CTGTTTGGTTGGTCTGATGTGGCTGTCATACTTTATTGCCAGTTTTCGTTTGTTC GCCCGTACACGCTCTATGTGGAGCTTCAACCCAGAGACAAACATTCTGTTGAAT GTTCCTCTGCATGGCACCATTCTGACGCGTCCATTATTAGAGAGTGAATTAGTC ATCGGAGCTGTTATTCTGCGCGGACACCTTCGTATCGCCGGTCATCACTTGGGT CGTTGCGACATCAAGGACTTACCAAAAGAAATTACAGTGGCTACATCACGCACC CTTTCCTATTATAAATTGGGTGCCTCACAACGCGTTGCCGGAGATTCGGGATTT GCTGCTTACTCACGTTACCGTATCGGAAATTACAAACTGAATACAGACCACTCTA GCTCATCCGATAACATTGCGCTTTTAGTGCAGTAActcgagccttaggagatccggctgctaa caaagcccgaaaggaagctgagCACTTTAGTTACAACATACTTATTgcctcgg

[0539] REFERENCES

[0540] 1 . Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, Jiang YZ, Xiong Y, Li YJ, Li XW, Li H, Fan GH, Gu XY, Xiao Y, Gao H, Xu JY, Yang F, Wang XM, Wu C, Chen L, Liu YW, Liu B, Yang J, Wang XR, Dong J, Li L, Huang CL, Zhao JP, Hu Y, Cheng ZS, Liu LL, Qian ZH, Qin C, Jin Q, Cao B, Wang JW. 2020. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 133:1015-1024.

[0541] 2. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, Mukhopadhyay S, Stroberg E, Duval EJ, Barton LM, Hajj Hussein I. 2020. COVID-19: A Multidisciplinary Review. Front Public Heal 8:1-20.

[0542] 3. Carter LJ, Garner L V., Smoot JW, Li Y, Zhou Q, Saveson CJ, Sasso JM, Gregg AC, Soares DJ, Beskid TR, Jervey SR, Liu C. 2020. Assay Techniques and Test Development for COVID-19 Diagnosis. ACS Cent Sci 6:591-605.

[0543] 4. Emmerich P, von Possel R, Hemmer CJ, Fritzsche C, Geerdes-Fenge H, Menge B, Messing C, Borchardt-Lohdlter V, Deschermeier C, Steinhagen K. 2021 . Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods. J Med Virol 93:5816-5824.

[0544] 5. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang QW, Xu SY, Zhu HD, Xu YC, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 71 :778-785.

[0545] 6. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, Sun R, Wang Y, Hu B, Chen W, Zhang Y, Wang J, Huang B, Lin Y, Yang J, Cai W, Wang X, Cheng J, Chen Z, Sun K, Pan W, Zhan Z, Chen L, Ye F. 2020. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 92:1518-1524.

[0546] 7. Chilamakuri R, Agarwal S. 2021. Covid-19: Characteristics and therapeutics. Cells 10:1-29.

[0547] 8. Brochot E, Demey B, Touze A, Belouzard S, Dubuisson J, Schmit JL, Duverlie G, Francois C, Castelain S, Helle F. 2020. Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals. Front Microbiol 11 :1-8.

[0548] 9. Roback JD, Guarner J. 2020. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA 323:1561-1562.

[0549] 10. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, Lan Z, Law S, MacLean E, Trajman A, Menzies D, Benedetti A, Khan FA. 2020. Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis. BMJ 370.

[0550] 11 . Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez- Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Feigner PL, Moran T, Garcia- Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti 0, Hepojoki JM, Simon V, Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 26:1033-1036.

[0551] 12. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, Pu A, Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi- Tehrani P, Guvenc F, Budylowski P, Li A, Paterson A, Yun YF, Marin LM, Caldwell L, Wrana JL, Colwill K, Sicheri F, Mubareka S, Gray-Owen SD, Drews SJ, Siqueira WL, Bamos-Rodiles M, Ostrowski M, Rini JM, Durocher Y, McGeer AJ, Gommerman JL, Gingras AC. 2020. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol 5:1-20.

[0552] 13. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. 2020. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 57:1-15.

[0553] 14. Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, Terenzi G, Liotti I, Ciotta G, Taddei C, Benucci M, Casprini P, Veneziani F, Fabbri S, Pompetti A, Manfredi M. 2020. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol 92:1671-1675.

[0554] 15. Okba NMA, Muller MA, Li W, Wang C, Geurtsvankessel CH, Corman VM, Larners MM, Sikkema RS, Bruin E De, Chandler FD, Yazdanpanah Y, Hingrat Q Le, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. 2020. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 26:1478-1488.

[0555] 16. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budylowski P, Dupuis AP, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K, McGeer AJ, Mubareka S, Gommerman JL, Durocher Y, Ostrowski M, McDonough KA, Drebot MA, Drews SJ, Rini JM, Gingras AC. 2020. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 5:1-26.

[0556] 17. Shirshahi V, Liu G. 2021 . Enhancing the analytical performance of paper lateral flow assays: From chemistry to engineering. TrAC - Trends Anal Chem 136:116200.

[0557] 18. Ni Y, Rosier BJHM, van Aalen EA, Hanckmann ETL, Biewenga L, Pistikou AMM, Timmermans B, Vu C, Roos S, Arts R, Li W, de Greet TFA, van Borren MMGJ, van Kuppeveld FJM, Bosch BJ, Merkx M. 2021. A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays. Nat Commun 12:1-12.

[0558] 19. Elledge SK, Zhou XX, Byrnes JR, Martinko AJ, Lui I, Pance K, Lim SA, Glasgow JE, Glasgow AA, Turcios K, Iyer NS, Torres L, Peluso MJ, Henrich TJ, Wang TT, Tato CM, Leung KK, Greenhouse B, Wells JA. 2021. Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nat Biotechnol 39:928-935.

[0559] 20. Yao Z, Drecun L, Aboualizadeh F, Kim SJ, Li Z, Wood H, Valcourt EJ, Manguiat K, Plenderleith S, Yip L, Li X, Zhong Z, Yue FY, Closas T, Snider J, Tomic J, Drews SJ, Drebot MA, McGeer A, Ostrowski M, Mubareka S, Rini JM, Owen S, Stagljar I. 2021 . A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies. Nat Commun 12.

[0560] 21. Matthews Q, da Silva SJR, Norouzi M, Pena LJ, Pardee K. 2020. Adaptive, diverse and de-centralized diagnostics are key to the future of outbreak response. BMC Biol 18:1-5. 22. Silverman AD, Karim AS, Jewett MC. 2020. Cell-free gene expression: an expanded repertoire of applications. Nat Rev Genet 21 : 151 -170.

[0561] 23. Garenne D, Haines MC, Romantseva EF, Freemont P, Strychalski EA, Noireaux V. 2021. Cell-free gene expression. Nat Rev Methods Prim 1.

[0562] 24. Pardee K, Slomovic S, Nguyen PQ, Lee JW, Donghia N, Burrill D, Ferrante T, McSorley FR, Furuta Y, Vernet A, Lewandowski M, Boddy CN, Joshi NS, Collins J J. 2016. Portable, On-Demand Biomolecular Manufacturing. Cell

[0563] 167:248-259. e12.

[0564] 25. Pardee K, Green AA, Takahashi MK, Braff D, Lambert G, Lee JW, Ferrante T, Ma D, Donghia N, Fan M, Daringer NM, Bosch I, Dudley DM, O’Connor DH, Gehrke L, Collins JJ. 2016. Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. Cell 165:1255-1266.

[0565] 26. Amalfitano E, Karlikow M, Norouzi M, Jaenes K, Cicek S, Masum F, Sadat Mousavi P, Guo Y, Tang L, Sydor A, Ma D, Pearson JD, Trcka D, Pinette M, Ambagala A, Babiuk S, Pickering B, Wrana J, Bremner R, Mazzulli T, Sinton D, Brumell JH, Green AA, Pardee K. 2021 . A glucose meter interface for point- of-care gene circuit-based diagnostics. Nat Commun 12:724.

[0566] 27. Varasteh Moradi S, Gagoski D, Mureev S, Walden P, McMahon KA, Parton RG, Johnston WA, Alexandrov K. 2020. Mapping Interactions among Cell-Free Expressed Zika Virus Proteins. J Proteome Res 19:1522-1532.

[0567] 28. Stech M, Kubick S. 2015. Cell-free synthesis meets antibody production: A review. Antibodies 4:12-33.

[0568] 29. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. 2012. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci 109:E690-E697.

[0569] 30. Norouzi M, Panfilov S, Pardee K. 2021. High-Efficiency Protection of Linear DNA in Cell-Free Extracts from Escherichia coli and Vibrio natriegens. ACS Synth Biol 10:1615-1624.

[0570] 31 . Keeble AH, Banerjee A, Ferla MP, Reddington SC, Anuar INAK, Howarth M. 2017. Evolving Accelerated Amidation by SpyTag / SpyCatcher to Analyze Membrane Dynamics. Angew Chemie - Int Ed 56:16521-16525.

[0571] 32. Lam SS, Martell JD, Kamer KJ, Deerinck TJ, Ellisman MH, Mootha VK, Ting AY. 2014. Directed evolution of APEX2 for electron microscopy and proximity labeling. Nat Methods 12:51-54.

[0572] 33. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow DS, Davey RT, Cohen JI. 2020. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis 222:206- 213.

[0573] 34. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z, Zheng S. 2020. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS- CoV-2. J Clin Microbiol 58:1-7.

[0574] 35. Heinz FX, Stiasny K. 2021 . Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action, npj Vaccines 6.

[0575] 36. Mattiuzzo G, Bentley EM, Hassall M, Routley S. 2020. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. World Heal Organ 9-10.

[0576] 37. Griffin BD, Warner BM, Chan M, Valcourt E, Tailor N, Banadyga L, Leung A, He S, Boese AS, Audet J, Cao W, Moffat E, Garnett L, Tierney K, Tran KN, Albietz A, Manguiat K, Soule G, Bello A, Vendramelli R, Lin J, Deschambault Y, Zhu W, Wood H, Mubareka S, Safronetz D, Strong JE, Embury-Hyatt C, Kobasa D. 2021 . Host parameters and mode of infection influence outcome in SARS-CoV-2-infected hamsters. iScience 24:103530.

[0577] 38. Mruk DD, Cheng CY. 2011 . Enhanced chemiluminescence (ECL) for routine immunoblotting. Spermatogenesis 1 :121-122.

[0578] 39. Keeble AH, Howarth M. 2019. Insider information on successful covalent protein coupling with help from SpyBank. Methods Enzymol 617:443-461.

[0579] 40. Ganapathy US, Bai L, Wei L, Eckartt KA, Lett CM, Previti ML, Carrico IS, Seeliger JC. 2018. Compartment-Specific Labeling of Bacterial Periplasmic Proteins by Peroxidase-Mediated Biotinylation. ACS Infect Dis 4:918-925.

[0580] 41. Leeman M, Choi J, Hansson S, Storm MU, Nilsson L. 2018. Proteins and antibodies in serum, plasma, and whole blood — size characterization using asymmetrical flow field-flow fractionation (AF4). Anal Bioanal Chem 410:4867- 4873.

[0581] 42. Liu H, He P, Meng F, Jiang M, Xiong J, Li J, Yu J. 2021 . IMMUNOASSAYS A Semiautomated Luciferase Immunoprecipitation Assay for.

[0582] 43. Gerdts V, Wilson HL, Meurens F, Van den Hurk S van DL, Wilson D, Walker S, Wheler C, Townsend H, Potter AA. 2015. Large animal models for vaccine development and testing. ILAR J 56:53-62.

[0583] 44. Rushton J, Gilbert W. 84 sg / 9 33:1-18.

[0584] 45. Prevost J, Gasser R, Beaudoin-Bussieres G, Richard J, Duerr R, Laumaea A, Anand SP, Goyette G, Benlarbi M, Ding S, Medjahed H, Lewin A, Perreault J, Tremblay T, Gendron-Lepage G, Gauthier N, Carrier M, Marcoux D, Piche A, Lavoie M, Benoit A, Loungnarath V, Brochu G, Haddad E, Stacey HD, Miller MS, Desforges M, Talbot PJ, Maule GTG, Cote M, Therrien C, Serhir B, Bazin R, Roger M, Finzi A. 2020. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Med 1 .

[0585] 46. Gregorio NE, Levine MZ, Oza JP. 2019. A user’s guide to cell-free protein synthesis. Methods Protoc 2:1-34.

[0586] 47. Welsh JP, Lu Y, He X-S, Greenberg HB, Swartz JR. 2012. Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens. Biotechnol Bioeng2012 / 08 / 16. 109:2962-2969.

[0587] 48. Viranaicken W, Nativel B, Krejbich-Trotot P, Harrabi W, Bos S, El Kalamouni C, Roche M, Gadea G, Despres P. 2017. ClearColi BL21 (DE3)-based expression of Zika virus antigens illustrates a rapid method of antibody production against emerging pathogens. Biochimie 142:179-182.

[0588] 49. Yamaoka Y, Matsuyama S, Fukushi S, Matsunaga S, Matsushima Y, Kuroyama H, Kimura H, Takeda M, Chimuro T, Ryo A. 2016. Development of Monoclonal Antibody and Diagnostic Test for Middle East Respiratory Syndrome Coronavirus Using Cell-Free Synthesized Nucleocapsid Antigen. Front Microbiol 7:509.

[0589] 50. Levine MZ, Gregorio NE, Jewett MC, Watts KR, Oza JP. 2019. Escherichia coH- Based Cell-Free Protein Synthesis: Protocols for a robust, flexible, and accessible platform technology. J Vis Exp 1-11

[0590] Although various embodiments of the disclosure have been described and illustrated, it will be apparent to those skilled in the art in light of the present description that numerous modifications and variations can be made. The scope of the invention is defined more particularly in the appended claims.

Claims

CLAIMSWhat is claimed is:1 . A method of detecting an antibody of interest in a humoral fluid comprising:(a) spotting humoral fluid from a subject directly on a solid support thereby immobilizing antibodies within the humoral fluid directly onto the solid support (“spotted solid support”);(b) contacting the spotted solid support with a fusion protein comprising an antigen of the antibody of interest and a primary tag such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen;(c) contacting the spotted solid support contacted with the fusion protein with a secondary detection reagent conjugated to a detectable label, the secondary detection reagent having affinity for the primary tag of the fusion protein to form a complex; and(d) detecting presence of a signal from the detectable label, wherein presence of the signal from the detectable label indicates the presence of the antibody of interest in the humoral fluid.

2. The method of claim 1 , wherein the fusion protein is encoded from a linear DNA template in a cell-free expression reaction mixture or is provided in purified form.

3. The method of claim 1 or claim 2, wherein the primary tag and the secondary detection reagent comprise a SpyTag (or a SpyTag-sequence-specific nickel-assisted cleavage tag (SpyTag-SNAC tag)) and SpyCatcher; or Isopeptag and pilin-C; or SnoopTag and SnoopCatcher; or DogTag and SnoopTagJr; or SdyTag and SdyCatcher.

4. The method of claim 1 or claim 2, wherein the primary tag and the secondary detection reagent comprise a SpyTag and SpyCatcher.

5. The method of claim 4, wherein the SpyCatcher is produced by E. co / / -based expression system.

6. The method according to any one of claims 1 to 5, wherein the secondary detection reagent comprises SpyCatcher conjugated to a peroxidase, and wherein step (d) comprises (i) contacting the blotting membrane to a solution comprising hydrogen peroxide (H2O2) and at least one readout substrate, wherein the at least one readout substrate can be converted to a readout product in the presence of the H2O2, and (ii) detecting the presence of the readout product.

7. The method of claim 6, wherein the peroxidase is Apex2 or HRP.

8. The method according to any one of claims 1 to 5, wherein the secondary reagent comprises SpyCatcher conjugated to a reporter that does not require exogenous hydrogen peroxide.

9. The method according to any one of claims 1 to 8, wherein the solid support is a nitrocellulose membrane, or a PVDF membrane or functionalized glass or plastic slides or beads.

10. The method according to any one of claims 1 to 9, wherein the solid support includes a grid of multiple spots, and wherein the humoral fluid is dispensed onto individual spots of the multiple spots.11 . The method according to any one of claims 1 to 10, wherein the humoral fluid is at least one of saliva, tears, mucus, breast milk, intestinal fluid, serum, plasma, blood, and vitreous fluid.

12. A kit for detecting an antibody of interest in a humoral fluid comprising:(a) a solid support for immobilizing antibodies in the humoral fluid;(b) a fusion protein comprising an antigen of the antibody of interest and a primary tag;(c) a secondary detection reagent conjugated to a detectable label; and(d) instructions for detecting the antibody of interest, wherein the instructions comprise:(i) spotting the humoral fluid from a subject directly on the solid support thereby immobilizing antibodies within the humoral fluid directly onto the blotting membrane (“spotted solid support”);(ii) contacting the spotted solid support with the fusion protein such that if the antibody of interest is present in the humoral fluid it serves as a capture probe for the antigen;(iii) contacting the solid support contacted with the fusion protein with the secondary detection reagent conjugated to the detectable label; and (iv) detecting presence of a signal from the detectable label, wherein presence of the signal from the detectable label indicates the presence of the antibody of interest in the humoral fluid.

13. A chimera protein comprising SpyCatcher2 conjugated to Apex2.

14. The chimera protein of claim 13 comprising amino acid SEQ ID NO:

2.

15. The chimera protein of claim 13, wherein the chimera protein is encoded by a DNA sequence comprising SEQ ID NO: 1.

16. A DNA sequence encoding for the chimera protein of claim 13.

17. The DNA sequence of claim 16, wherein the DNA sequence comprises SEQ ID NO: 1.

Images